{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Semalytics walkthrough\n",
    "\n",
    "Welcome to the Semalytics demo!\n",
    "\n",
    "\n",
    "<a id='intro'></a>\n",
    "## Introduction\n",
    "\n",
    "This is an extended computational narrative focusing on the platform **Semalytics**, a semantic-based tool for analyzing hierarchical data in translational cancer research. This demo is bundled with the paper:\n",
    "\n",
    "> _**Semalytics: a semantic analytics platform for the exploration of distributed and heterogenous cancer data (in translational research)**_\n",
    "\n",
    "Biological annotations are modeled in a new **Semantic Web** fashion and are connected to **Wikidata** for knowledge expansion. Please, note that Semalytics explores annotations that are highly scattered along hierarchical data.\n",
    "\n",
    "In this notebook, we are going to use Semalytics for analyzing a test dataset in order to investigate gene alteration-drug interactions. In particular, we focus on the response to the **Cetuximab**, an epidermal growth factor inhibitor used for the treatment of several cancer types, such as the colorectal cancer. Each cancer is a complex and variable system with unique characteristics at the molecular level, which may determine drugs performance. In this demo, we match drug responses data with annotations related to a set of 4 genes:\n",
    "\n",
    "* BRAF\n",
    "* EGFR\n",
    "* HER2 \n",
    "* KRAS\n",
    "\n",
    "which are known to be relevant to Cetuximab response in colorectal cancer.\n",
    "\n",
    "* In [Chapter 1](#insights), we show how the platform can be used for getting basic data insights about genomic landscapes and drug responses. In particular, we use Semalytics to identify an investigation set (i.e., data trees with both genomic and pharmacological annotations).\n",
    "\n",
    "* In [Chapter 2](#inside), we explore data into the investigation set. First, we get the list of variants for the genes in the panel. Then, we explore the co-occurence of genomic variants and responses to Cetuximab.\n",
    "\n",
    "* Finally, in [Chapter 3](#wikidata), we use Semalytics for analyzing local data harnessing the extended information of Wikidata, thus gaining new analytical options on our local database. For example, we use federated queries to explore of data about drugs different from Cetuximab, which we do not store and maintain locally.  \n",
    "\n",
    "See the aforementioned article for further details.\n",
    "\n",
    "\n",
    "## Table of contents\n",
    "\n",
    "* [Introduction](#intro)\n",
    "* [General settings](#settings)\n",
    "* [Chapter 1 - Basic insights](#insights)\n",
    "    - [Annotated nodes](#annotated)\n",
    "    - [Genomic annotations](#genes)\n",
    "    - [Response annotations](#mice) \n",
    "    - [Investigation set: genomic and responses annotations](#miceanddrug)\n",
    "* [Chapter 2 - Inside the investigation set](#inside)\n",
    "    - [Variants of non-responders](#variantsnonresp)\n",
    "    - [Getting basic data for co-occurence analysis](#matchinggetdata)\n",
    "    - [Matching annotations in the investigation set](#mset)\n",
    "    - [Matching `feature_amplification` only](#mamplsubset)\n",
    "    - [Matching `sequence_alteration` only](#mseqsubset)\n",
    "* [Chapter 3 - Querying data with knowledge and Wikidata](#wikidata)\n",
    "    - [Drugs targeting gene products](#drugsrole)\n",
    "    - [Drug information: dabrafenib](#dabrafenib)\n",
    "    - [Querying variants](#queryinnvar)\n",
    "    - [Positive therapeutic predictors](#pos)\n",
    "    - [Negative therapeutic predictors](#neg)\n",
    "    - [Drugs predictions for a specific case](#case)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='settings'></a>\n",
    "## General settings\n",
    "\n",
    "General imports and vars"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import utils\n",
    "import pandas as pd\n",
    "from IPython.display import SVG, display\n",
    "\n",
    "# SPARQL endpoints\n",
    "\n",
    "# Semalytics (i.e., local data)\n",
    "# 14,281,125 explicit triples\n",
    "#  2,391,980 inferred triples\n",
    "SEMALYTICS_ENDPOINT = 'http://semalytics:7200/repositories/annotationDB'\n",
    "\n",
    "# Remote knowledge base\n",
    "WIKIDATA_ENDPOINT = 'https://query.wikidata.org/sparql'\n",
    "\n",
    "# genes panel\n",
    "PANEL = {'BRAF','EGFR','ERBB2','KRAS'}\n",
    "\n",
    "# investigated variants\n",
    "VARIANTS = ':sequence_alteration :feature_amplification'\n",
    "\n",
    "# enable inline plotting\n",
    "%matplotlib inline\n",
    "\n",
    "# do not truncate data in tables\n",
    "pd.set_option('display.max_colwidth', -1)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='insights'></a>\n",
    "## Chapter 1 - Basic insights\n",
    "\n",
    "We query Semalytics data for getting basic insights. Semalytics returns immediately analytics on scattered annotations.\n",
    "\n",
    "<a id='annotated'></a>\n",
    "### Annotated nodes\n",
    "\n",
    "We use the following query to retrieve **annotated nodes** (samples for genes or mice for drug reponses)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "there are 3917 annotated nodes in trees\n"
     ]
    }
   ],
   "source": [
    "# the query\n",
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX onto: <http://www.ontotext.com/>\n",
    "select (count(distinct ?node) as ?nodes)\n",
    "from onto:disable-sameAs\n",
    "where {\n",
    "    ?case a :Case ;\n",
    "          :hasDescendant ?node .\n",
    "    ?node a :Bioentity ;\n",
    "          :has_annotation ?ann .\n",
    "}\n",
    "\"\"\"\n",
    "\n",
    "# get data\n",
    "result_table = utils.query(SEMALYTICS_ENDPOINT, my_query)\n",
    "\n",
    "# there you go!\n",
    "result = result_table['nodes.value'][0] \n",
    "print(f'there are {result} annotated nodes in trees')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='genes'></a>\n",
    "### Genomic annotations\n",
    "\n",
    "Let $\\mathcal{G}$ be the set of data trees with annotations about `:sequence_alteration` or `:feature_amplification` for **genes in the panel**. We build $\\mathcal{G}$ with the following query:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "there are 354 cases annotated with 1+ variant(s) in the panel (KRAS, EGFR, BRAF, HER2)\n"
     ]
    }
   ],
   "source": [
    "# Cases with annotations in the genes panel\n",
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX onto: <http://www.ontotext.com/>\n",
    "select (count(distinct ?case) as ?cases) \n",
    "from onto:disable-sameAs\n",
    "where { \n",
    "    ?case a :Case ;\n",
    "          :hasDescendant ?node .\n",
    "    ?node :has_annotation ?ann .\n",
    "    ?ann :has_reference ?ref .\n",
    "    ?gene :has_variant ?ref.\n",
    "    ?gene :symbol ?geneSymbol\n",
    "    VALUES ?geneSymbol {'KRAS' 'EGFR' 'BRAF' 'ERBB2'}\n",
    "    ?ref a ?annotation_Type .\n",
    "    VALUES ?annotation_Type { \"\"\"+VARIANTS+\"\"\"  }\n",
    "}\n",
    "\"\"\"\n",
    "\n",
    "# get data\n",
    "result_table = utils.query(SEMALYTICS_ENDPOINT, my_query)\n",
    "\n",
    "# there you go!\n",
    "result = result_table['cases.value'][0] \n",
    "print(f'there are {result} cases annotated with 1+ variant(s) in the panel (KRAS, EGFR, BRAF, HER2)')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='mice'></a>\n",
    "### Response annotations\n",
    "\n",
    "Let $\\mathcal{D}$ be the set of data trees with annotated mice about **pharmacological responses**. We build $\\mathcal{D}$ with the following query:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "there are 238 cases annotated with 1+ pharmacological response(s) for the CETUXIMAB\n"
     ]
    }
   ],
   "source": [
    "# Cases with pharmacological annotations\n",
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX onto: <http://www.ontotext.com/>\n",
    "select ?drugName (count(distinct ?case) as ?cases)\n",
    "from onto:disable-sameAs\n",
    "where {\n",
    "    ?case a :Case ;\n",
    "          :hasDescendant ?mouse .\n",
    "    ?mouse a :Biomouse ;\n",
    "           :has_annotation ?ann .\n",
    "    ?ann :has_reference ?ref .\n",
    "    ?ref a :drug_response .\n",
    "    ?drug :has_drug_response ?ref;\n",
    "          :name ?drugName .\n",
    "}\n",
    "GROUP BY ?drugName\n",
    "\"\"\"\n",
    "\n",
    "# get data\n",
    "result_table = utils.query(SEMALYTICS_ENDPOINT, my_query)\n",
    "\n",
    "# there you go!\n",
    "drug,cases = result_table['drugName.value'][0],result_table['cases.value'][0]\n",
    "print(f'there are {cases} cases annotated with 1+ pharmacological response(s) for the {drug}')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='miceanddrug'></a>\n",
    "### Investigation set: genomic and responses annotations\n",
    "\n",
    "Let $\\mathcal{S} = (\\mathcal{G} \\cap \\mathcal{D})$ be the investigation scope (i.e., data trees with both genomic and pharmacological annotations). We get it through this query:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "there are 113 cases annotated with 1+ pharmacological response(s) AND 1+ variant(s)\n"
     ]
    }
   ],
   "source": [
    "# Cases with pharmacological and genomic annotations\n",
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX onto: <http://www.ontotext.com/>\n",
    "select (count(distinct ?case) as ?cases)\n",
    "from onto:disable-sameAs\n",
    "where {\n",
    "    ?case a :Case ;\n",
    "          :hasDescendant ?mouse ;\n",
    "          :hasDescendant ?node .\n",
    "    ?mouse a :Biomouse ;\n",
    "           :has_annotation ?ann .\n",
    "    ?ann :has_reference ?ref .\n",
    "    ?ref a :drug_response .\n",
    "    ?node :has_annotation ?ann2 .\n",
    "    ?ann2 :has_reference ?ref2 .\n",
    "    ?gene :has_variant ?ref2.\n",
    "    ?gene :symbol ?geneSymbol\n",
    "    VALUES ?geneSymbol {'KRAS' 'EGFR' 'BRAF' 'ERBB2'}\n",
    "    ?ref2 a ?annotation_Type.\n",
    "    VALUES ?annotation_Type { \"\"\"+VARIANTS+\"\"\" }\n",
    "}\n",
    "\"\"\"\n",
    "\n",
    "# get data\n",
    "result_table = utils.query(SEMALYTICS_ENDPOINT, my_query)\n",
    "\n",
    "# there you go!\n",
    "investigation_scope = result_table['cases.value'][0]\n",
    "print(f'there are {investigation_scope} cases annotated with 1+ pharmacological response(s) AND 1+ variant(s)')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='inside'></a>\n",
    "## Chapter 2 - Inside the investigation set\n",
    "\n",
    "In this section we analyze annotation types for cases in the investigation set. Moreover, we exploit Semalytics for matching variants against responses to Cetuximab.\n",
    "\n",
    "<a id='variantsnonresp'></a>\n",
    "### Variants of non responders\n",
    "\n",
    "With the following query, we get the **variants list** of non-responder cases. The column `alt_p.value` represents the type of `point_mutation`."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>case.value</th>\n",
       "      <th>geneSymbol.value</th>\n",
       "      <th>type.value</th>\n",
       "      <th>alt_p.value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>CRC0019</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G13D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>CRC0021</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12C</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>CRC0021</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12V</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>CRC0024</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G13C</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>CRC0027</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G13D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>CRC0028</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G13D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>CRC0031</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>CRC0053</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>A146T</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>CRC0055</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12V</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>CRC0058</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12V</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>CRC0060</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12V</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>CRC0063</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12V</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>CRC0064</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>CRC0067</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>I36M</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>CRC0068</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12C</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>CRC0070</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>CRC0073</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12C</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>CRC0077</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>CRC0079</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>V600E</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>CRC0080</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td>feature_amplification</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>CRC0082</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G13D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>CRC0085</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>A146T</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>CRC0094</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12C</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>CRC0105</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>feature_amplification</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>CRC0106</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>V600E</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>CRC0112</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td>feature_amplification</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>CRC0118</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>V600E</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>CRC0124</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>H878Y</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>CRC0124</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td>feature_amplification</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>CRC0125</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>K117N</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>CRC0315</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G13D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>CRC0323</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>V600E</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>63</th>\n",
       "      <td>CRC0324</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12V</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>64</th>\n",
       "      <td>CRC0348</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>CRC0349</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>66</th>\n",
       "      <td>CRC0382</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12C</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>CRC0438</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>Q61K</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>68</th>\n",
       "      <td>CRC0468</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12V</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>CRC0479</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G13D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>CRC0480</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>V600E</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>CRC0481</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G13D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>CRC0481</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>feature_amplification</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>CRC0484</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>V600E</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>CRC0504</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G13D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>CRC0504</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>R678Q</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>CRC0508</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>feature_amplification</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>77</th>\n",
       "      <td>CRC0527</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>K601N</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>CRC0527</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>feature_amplification</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>CRC0528</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>V600E</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>80</th>\n",
       "      <td>CRC0610</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>feature_amplification</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>81</th>\n",
       "      <td>CRC0626</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>A146V</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>CRC0714</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G13D</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>CRC0729</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td>feature_amplification</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>CRC0753</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12V</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>CRC1063</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>K601E</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>CRC1063</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>T241M</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>CRC1138</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>K601E</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>CRC1169</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>feature_amplification</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>CRC1182</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>point_mutation</td>\n",
       "      <td>G12A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>CRC1278</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>feature_amplification</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>91 rows Ã— 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   case.value geneSymbol.value             type.value alt_p.value\n",
       "0   CRC0019    KRAS             point_mutation         G13D      \n",
       "1   CRC0021    KRAS             point_mutation         G12C      \n",
       "2   CRC0021    KRAS             point_mutation         G12V      \n",
       "3   CRC0024    KRAS             point_mutation         G13C      \n",
       "4   CRC0027    KRAS             point_mutation         G13D      \n",
       "5   CRC0028    KRAS             point_mutation         G13D      \n",
       "6   CRC0031    KRAS             point_mutation         G12D      \n",
       "7   CRC0053    KRAS             point_mutation         A146T     \n",
       "8   CRC0055    KRAS             point_mutation         G12V      \n",
       "9   CRC0058    KRAS             point_mutation         G12V      \n",
       "10  CRC0060    KRAS             point_mutation         G12V      \n",
       "11  CRC0063    KRAS             point_mutation         G12V      \n",
       "12  CRC0064    KRAS             point_mutation         G12D      \n",
       "13  CRC0067    KRAS             point_mutation         I36M      \n",
       "14  CRC0068    KRAS             point_mutation         G12C      \n",
       "15  CRC0070    KRAS             point_mutation         G12D      \n",
       "16  CRC0073    KRAS             point_mutation         G12C      \n",
       "17  CRC0077    KRAS             point_mutation         G12D      \n",
       "18  CRC0079    BRAF             point_mutation         V600E     \n",
       "19  CRC0080    ERBB2            feature_amplification            \n",
       "20  CRC0082    KRAS             point_mutation         G13D      \n",
       "21  CRC0085    KRAS             point_mutation         A146T     \n",
       "22  CRC0094    KRAS             point_mutation         G12C      \n",
       "23  CRC0105    EGFR             feature_amplification            \n",
       "24  CRC0106    BRAF             point_mutation         V600E     \n",
       "25  CRC0112    ERBB2            feature_amplification            \n",
       "26  CRC0118    BRAF             point_mutation         V600E     \n",
       "27  CRC0124    ERBB2            point_mutation         H878Y     \n",
       "28  CRC0124    ERBB2            feature_amplification            \n",
       "29  CRC0125    KRAS             point_mutation         K117N     \n",
       "..      ...     ...                        ...           ...     \n",
       "61  CRC0315    KRAS             point_mutation         G13D      \n",
       "62  CRC0323    BRAF             point_mutation         V600E     \n",
       "63  CRC0324    KRAS             point_mutation         G12V      \n",
       "64  CRC0348    KRAS             point_mutation         G12D      \n",
       "65  CRC0349    KRAS             point_mutation         G12D      \n",
       "66  CRC0382    KRAS             point_mutation         G12C      \n",
       "67  CRC0438    KRAS             point_mutation         Q61K      \n",
       "68  CRC0468    KRAS             point_mutation         G12V      \n",
       "69  CRC0479    KRAS             point_mutation         G13D      \n",
       "70  CRC0480    BRAF             point_mutation         V600E     \n",
       "71  CRC0481    KRAS             point_mutation         G13D      \n",
       "72  CRC0481    EGFR             feature_amplification            \n",
       "73  CRC0484    BRAF             point_mutation         V600E     \n",
       "74  CRC0504    KRAS             point_mutation         G13D      \n",
       "75  CRC0504    ERBB2            point_mutation         R678Q     \n",
       "76  CRC0508    EGFR             feature_amplification            \n",
       "77  CRC0527    BRAF             point_mutation         K601N     \n",
       "78  CRC0527    EGFR             feature_amplification            \n",
       "79  CRC0528    BRAF             point_mutation         V600E     \n",
       "80  CRC0610    EGFR             feature_amplification            \n",
       "81  CRC0626    KRAS             point_mutation         A146V     \n",
       "82  CRC0714    KRAS             point_mutation         G13D      \n",
       "83  CRC0729    ERBB2            feature_amplification            \n",
       "84  CRC0753    KRAS             point_mutation         G12V      \n",
       "85  CRC1063    BRAF             point_mutation         K601E     \n",
       "86  CRC1063    BRAF             point_mutation         T241M     \n",
       "87  CRC1138    BRAF             point_mutation         K601E     \n",
       "88  CRC1169    EGFR             feature_amplification            \n",
       "89  CRC1182    KRAS             point_mutation         G12A      \n",
       "90  CRC1278    EGFR             feature_amplification            \n",
       "\n",
       "[91 rows x 4 columns]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX sesame: <http://www.openrdf.org/schema/sesame#>\n",
    "PREFIX onto: <http://www.ontotext.com/>\n",
    "select distinct ?case ?geneSymbol ?type ?alt_p\n",
    "from onto:disable-sameAs\n",
    "where {\n",
    "    ?case a :Case ;\n",
    "          :hasDescendant ?mouse ;\n",
    "          :hasDescendant ?node .\n",
    "    \n",
    "    ?mouse a :Biomouse ;\n",
    "           :has_annotation ?ann .\n",
    "    ?ann :has_reference ?ref .\n",
    "    ?ref a :DRCl_PD .\n",
    "    \n",
    "    ?node :has_annotation ?ann2 .\n",
    "    ?ann2 :has_reference ?ref2 .\n",
    "    ?gene :has_variant ?ref2 ;\n",
    "    :symbol ?geneSymbol\n",
    "    VALUES ?geneSymbol {'KRAS' 'EGFR' 'BRAF' 'ERBB2'}\n",
    "    ?ref2 a ?annotation_Type.\n",
    "    VALUES ?annotation_Type { :sequence_alteration :feature_amplification }\n",
    "    ?ref2 sesame:directType ?type.\n",
    "        OPTIONAL {?ref2 :alt_p ?alt_p }\n",
    "}\n",
    "ORDER BY ?case\n",
    "\"\"\"\n",
    "\n",
    "# get data\n",
    "result_table = utils.query(SEMALYTICS_ENDPOINT, my_query)\n",
    "\n",
    "# filter URIs prefixes\n",
    "utils.filter_prefixes(result_table)\n",
    "\n",
    "\n",
    "# there you go!\n",
    "result_table[['case.value', 'geneSymbol.value', 'type.value', 'alt_p.value']].fillna(\"\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='matchinggetdata'></a>\n",
    "### Getting basic data for co-occurence analysis\n",
    "\n",
    "Creating basic data for further investigations about gene variant - drug matching."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "# data collections\n",
    "cases_per_gene = dict()\n",
    "cases_per_variant = dict()\n",
    "cases_per_variant_per_gene = dict()\n",
    "cases_per_response = dict()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "We get **cases harboring 1+ variants for each gene in the panel**.\n",
    "\n",
    "Please, note that we are counting distinct cases per gene. Therefore, cases harboring multiple variants in the same gene will be counted only once."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Querying ERBB2\n",
      "Querying KRAS\n",
      "Querying EGFR\n",
      "Querying BRAF\n",
      "Cases outline:\n",
      "ERBB2: 11\n",
      "KRAS: 70\n",
      "EGFR: 29\n",
      "BRAF: 13\n"
     ]
    }
   ],
   "source": [
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX sesame: <http://www.openrdf.org/schema/sesame#>\n",
    "PREFIX onto: <http://www.ontotext.com/>\n",
    "select distinct ?case\n",
    "from onto:disable-sameAs\n",
    "where {{\n",
    "    ?case a :Case ;\n",
    "          :hasDescendant ?mouse ;\n",
    "          :hasDescendant ?node .\n",
    "\n",
    "    ?mouse a :Biomouse ;\n",
    "           :has_annotation ?ann .\n",
    "    ?ann :has_reference ?ref .\n",
    "\n",
    "    ?node :has_annotation ?ann2 .\n",
    "    ?ann2 :has_reference ?ref2 .\n",
    "    ?gene :has_variant ?ref2 ;\n",
    "          :symbol ?geneSymbol\n",
    "    VALUES ?geneSymbol {{'{}'}}\n",
    "    ?ref2 a ?annotation_Type.\n",
    "    VALUES ?annotation_Type {{ :sequence_alteration :feature_amplification }}\n",
    "    ?ref2 sesame:directType ?type. \n",
    "}}\"\"\"\n",
    "\n",
    "for gene in PANEL:\n",
    "    print (f'Querying {gene}')\n",
    "    result_table = utils.query(SEMALYTICS_ENDPOINT, my_query.format(gene))\n",
    "    cases_per_gene[gene] = set(result_table['case.value'])\n",
    "\n",
    "print ('Cases outline:')\n",
    "for key in cases_per_gene:\n",
    "    print(f'{key}: {len(cases_per_gene[key])}')\n",
    "    "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Then, we get cases **harboring 1+ `:sequence_alteration` or `:feature_amplification`**\n",
    "\n",
    "Again, please, note that we are counting distinct cases per gene. Therefore, cases harboring multiple variants in the same gene will be counted only once."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Querying sequence_alteration\n",
      "Querying feature_amplification\n",
      "Cases outline:\n",
      "\tsequence_alteration 88\n",
      "\tfeature_amplification 33\n"
     ]
    }
   ],
   "source": [
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX sesame: <http://www.openrdf.org/schema/sesame#>\n",
    "PREFIX onto: <http://www.ontotext.com/>\n",
    "select distinct ?case \n",
    "from onto:disable-sameAs\n",
    "where {{\n",
    "    ?case a :Case ;\n",
    "          :hasDescendant ?mouse ;\n",
    "          :hasDescendant ?node .\n",
    "\n",
    "    ?mouse a :Biomouse ;\n",
    "           :has_annotation ?ann .\n",
    "    ?ann :has_reference ?ref .\n",
    "\n",
    "    ?node :has_annotation ?ann2 .\n",
    "    ?ann2 :has_reference ?ref2 .\n",
    "    ?gene :has_variant ?ref2 ;\n",
    "          :symbol ?geneSymbol\n",
    "    VALUES ?geneSymbol {{'KRAS' 'EGFR' 'BRAF' 'ERBB2'}}\n",
    "    ?ref2 a ?annotation_Type.\n",
    "    VALUES ?annotation_Type {{ :{} }}\n",
    "    ?ref2 sesame:directType ?type. \n",
    "}}\"\"\"\n",
    "\n",
    "for variant in ['sequence_alteration', 'feature_amplification']:\n",
    "    print (f'Querying {variant}')\n",
    "    result_table = utils.query(SEMALYTICS_ENDPOINT, my_query.format(variant))\n",
    "    cases_per_variant[variant] =  set(result_table['case.value'])\n",
    "       \n",
    "\n",
    "print ('Cases outline:')\n",
    "for variant in cases_per_variant:\n",
    "    print(f'\\t{variant} {len(cases_per_variant[variant])}')\n",
    "    "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Besides, we get cases **harboring 1+ `:sequence_alteration` or `:feature_amplification` for each gene in the panel**.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Querying sequence_alteration\n",
      "Querying feature_amplification\n",
      "no data for feature_amplification - KRAS\n",
      "no data for feature_amplification - BRAF\n",
      "Cases outline:\n",
      "sequence_alteration\n",
      "\tERBB2 5\n",
      "\tKRAS 70\n",
      "\tEGFR 4\n",
      "\tBRAF 13\n",
      "feature_amplification\n",
      "\tERBB2 7\n",
      "\tEGFR 26\n"
     ]
    }
   ],
   "source": [
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX sesame: <http://www.openrdf.org/schema/sesame#>\n",
    "PREFIX onto: <http://www.ontotext.com/>\n",
    "select distinct ?case \n",
    "from onto:disable-sameAs\n",
    "where {{\n",
    "    ?case a :Case ;\n",
    "          :hasDescendant ?mouse ;\n",
    "          :hasDescendant ?node .\n",
    "\n",
    "    ?mouse a :Biomouse ;\n",
    "           :has_annotation ?ann .\n",
    "    ?ann :has_reference ?ref .\n",
    "\n",
    "    ?node :has_annotation ?ann2 .\n",
    "    ?ann2 :has_reference ?ref2 .\n",
    "    ?gene :has_variant ?ref2 ;\n",
    "          :symbol ?geneSymbol\n",
    "    VALUES ?geneSymbol {{'{}'}}\n",
    "    ?ref2 a ?annotation_Type.\n",
    "    VALUES ?annotation_Type {{ :{} }}\n",
    "    ?ref2 sesame:directType ?type. \n",
    "}}\"\"\"\n",
    "\n",
    "for variant in ['sequence_alteration', 'feature_amplification']:\n",
    "    print (f'Querying {variant}')\n",
    "    cases_per_variant_per_gene[variant] = dict()\n",
    "    for gene in PANEL:\n",
    "        result_table = utils.query(SEMALYTICS_ENDPOINT, my_query.format(gene, variant))\n",
    "        try:\n",
    "            cases_per_variant_per_gene[variant][gene] =  set(result_table['case.value'])\n",
    "        except KeyError:\n",
    "            print (f'no data for {variant} - {gene}')\n",
    "\n",
    "print ('Cases outline:')\n",
    "for variant in cases_per_variant_per_gene:\n",
    "        print(f'{variant}')\n",
    "        for gene in cases_per_variant_per_gene[variant]:\n",
    "            print(f'\\t{gene} {len(cases_per_variant_per_gene[variant][gene])}')\n",
    "    "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Variants summary:\n",
    "\n",
    "\n",
    "|    Gene  | All variant types | :feature_amplification  | :sequence_alteration |\n",
    "|-------------|-----|------------|-----|\n",
    "| Annotated   | 113 | 33         | 88  |\n",
    "| BRAF        | 13  | 0          | 13  |\n",
    "| EGFR        | 29  | 26         | 4   |\n",
    "| ERBB2       | 11  | 7          | 5   |\n",
    "| KRAS        | 70  | 0          | 70  |"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Finally, we get **cases per response type**."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Querying DRCl_OR\n",
      "Querying DRCl_SD\n",
      "Querying DRCl_PD\n",
      "Cases outline:\n",
      "DRCl_OR: 7\n",
      "DRCl_SD: 26\n",
      "DRCl_PD: 80\n"
     ]
    }
   ],
   "source": [
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX sesame: <http://www.openrdf.org/schema/sesame#>\n",
    "PREFIX onto: <http://www.ontotext.com/>\n",
    "select distinct ?case \n",
    "from onto:disable-sameAs\n",
    "where {{\n",
    "    ?case a :Case ;\n",
    "          :hasDescendant ?mouse ;\n",
    "          :hasDescendant ?node .\n",
    "\n",
    "    ?mouse a :Biomouse ;\n",
    "           :has_annotation ?ann .\n",
    "    ?ann :has_reference ?ref .\n",
    "    ?ref sesame:directType :{} .\n",
    "\n",
    "    ?node :has_annotation ?ann2 .\n",
    "    ?ann2 :has_reference ?ref2 .\n",
    "    ?gene :has_variant ?ref2 ;\n",
    "          :symbol ?geneSymbol\n",
    "    VALUES ?geneSymbol {{'KRAS' 'EGFR' 'BRAF' 'ERBB2'}}\n",
    "    ?ref2 a ?annotation_Type.\n",
    "    VALUES ?annotation_Type {{ :sequence_alteration :feature_amplification }}\n",
    "    ?ref2 sesame:directType ?type. \n",
    "}}\"\"\"\n",
    "\n",
    "for response in ['DRCl_OR', 'DRCl_SD', 'DRCl_PD']:\n",
    "    print (f'Querying {response}')\n",
    "    result_table = utils.query(SEMALYTICS_ENDPOINT, my_query.format(response))\n",
    "    cases_per_response[response] = set(result_table['case.value'])\n",
    "\n",
    "print ('Cases outline:')\n",
    "for key in cases_per_response:\n",
    "    print(f'{key}: {len(cases_per_response[key])}')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Since we are also interested in analyzing **variants co-occurrences**, we enumerate all possible combinations (i.e., the power set). We will use these data in the next sections."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(),\n",
       " ('BRAF',),\n",
       " ('ERBB2',),\n",
       " ('KRAS',),\n",
       " ('EGFR',),\n",
       " ('KRAS', 'EGFR'),\n",
       " ('KRAS', 'BRAF'),\n",
       " ('ERBB2', 'BRAF'),\n",
       " ('ERBB2', 'KRAS'),\n",
       " ('ERBB2', 'EGFR'),\n",
       " ('EGFR', 'BRAF'),\n",
       " ('ERBB2', 'EGFR', 'BRAF'),\n",
       " ('ERBB2', 'KRAS', 'EGFR'),\n",
       " ('ERBB2', 'KRAS', 'BRAF'),\n",
       " ('KRAS', 'EGFR', 'BRAF'),\n",
       " ('ERBB2', 'KRAS', 'EGFR', 'BRAF')]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# create variants co-occurrences list (i.e., the power set of {'BRAF','EGFR','ERBB2','KRAS'})\n",
    "variants_occurrences = list(utils.powerset(PANEL))\n",
    "variants_occurrences.sort(key=len)\n",
    "\n",
    "# just combinatorics\n",
    "variants_occurrences"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='mset'></a>\n",
    "### Matching annotations in the investigation set\n",
    "\n",
    "We analyze all annotated cases and we match drug information with gene variants data."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "113\n"
     ]
    }
   ],
   "source": [
    "# the investigation set\n",
    "tot = cases_per_gene['BRAF'] | cases_per_gene['EGFR'] | cases_per_gene['ERBB2'] | cases_per_gene['KRAS']\n",
    "\n",
    "print(len(tot))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>gene</th>\n",
       "      <th>case</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Annotated</td>\n",
       "      <td>113</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>13</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>70</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        gene  case\n",
       "0  Annotated  113 \n",
       "1  BRAF       13  \n",
       "2  EGFR       29  \n",
       "3  ERBB2      11  \n",
       "4  KRAS       70  "
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# create a new Semalytics analysis object\n",
    "a = utils.Analysis(tot, cases_per_gene, cases_per_response, variants_occurrences)\n",
    "\n",
    "# gene variants\n",
    "a.variants"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x11e684940>"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# plot variants distribution\n",
    "a.plot_variants()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>response_type</th>\n",
       "      <th>case</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>response</td>\n",
       "      <td>7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>neutral</td>\n",
       "      <td>26</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>progression</td>\n",
       "      <td>80</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  response_type  case\n",
       "0  response      7   \n",
       "1  neutral       26  \n",
       "2  progression   80  "
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# responses\n",
    "a.responses"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, '')"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 360x360 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# plot responses\n",
    "a.plot_responses()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>genes</th>\n",
       "      <th>DRCl_PD</th>\n",
       "      <th>DRCl_SD</th>\n",
       "      <th>DRCl_OR</th>\n",
       "      <th>tot</th>\n",
       "      <th>progression</th>\n",
       "      <th>neutral</th>\n",
       "      <th>response</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>(BRAF,)</td>\n",
       "      <td>13</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>13</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>(ERBB2,)</td>\n",
       "      <td>8</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>11</td>\n",
       "      <td>0.727273</td>\n",
       "      <td>0.0909091</td>\n",
       "      <td>0.181818</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>(KRAS,)</td>\n",
       "      <td>56</td>\n",
       "      <td>14</td>\n",
       "      <td>0</td>\n",
       "      <td>70</td>\n",
       "      <td>0.8</td>\n",
       "      <td>0.2</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>(EGFR,)</td>\n",
       "      <td>10</td>\n",
       "      <td>14</td>\n",
       "      <td>5</td>\n",
       "      <td>29</td>\n",
       "      <td>0.344828</td>\n",
       "      <td>0.482759</td>\n",
       "      <td>0.172414</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>(KRAS, EGFR)</td>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>6</td>\n",
       "      <td>0.5</td>\n",
       "      <td>0.5</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>(KRAS, BRAF)</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>(ERBB2, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>(ERBB2, KRAS)</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>(ERBB2, EGFR)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>(EGFR, BRAF)</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>(ERBB2, EGFR, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>(ERBB2, KRAS, EGFR)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>(ERBB2, KRAS, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>(KRAS, EGFR, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>(ERBB2, KRAS, EGFR, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                        genes  DRCl_PD  DRCl_SD  DRCl_OR  tot progression  \\\n",
       "0   (BRAF,)                    13       0        0        13   1            \n",
       "1   (ERBB2,)                   8        1        2        11   0.727273     \n",
       "2   (KRAS,)                    56       14       0        70   0.8          \n",
       "3   (EGFR,)                    10       14       5        29   0.344828     \n",
       "4   (KRAS, EGFR)               3        3        0        6    0.5          \n",
       "5   (KRAS, BRAF)               2        0        0        2    1            \n",
       "6   (ERBB2, BRAF)              0        0        0        0                 \n",
       "7   (ERBB2, KRAS)              1        0        0        1    1            \n",
       "8   (ERBB2, EGFR)              0        0        0        0                 \n",
       "9   (EGFR, BRAF)               1        0        0        1    1            \n",
       "10  (ERBB2, EGFR, BRAF)        0        0        0        0                 \n",
       "11  (ERBB2, KRAS, EGFR)        0        0        0        0                 \n",
       "12  (ERBB2, KRAS, BRAF)        0        0        0        0                 \n",
       "13  (KRAS, EGFR, BRAF)         0        0        0        0                 \n",
       "14  (ERBB2, KRAS, EGFR, BRAF)  0        0        0        0                 \n",
       "\n",
       "      neutral  response  \n",
       "0   0          0         \n",
       "1   0.0909091  0.181818  \n",
       "2   0.2        0         \n",
       "3   0.482759   0.172414  \n",
       "4   0.5        0         \n",
       "5   0          0         \n",
       "6                        \n",
       "7   0          0         \n",
       "8                        \n",
       "9   0          0         \n",
       "10                       \n",
       "11                       \n",
       "12                       \n",
       "13                       \n",
       "14                       "
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# variants vs responses\n",
    "a.matching.fillna(\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x11edb6160>"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# plot matching\n",
    "a.plot_matching()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='mamplsubset'></a>\n",
    "### Matching `feature_amplification` only\n",
    "\n",
    "We analyze cases with only 1+ `feature_amplification` (and with no `sequence_alteration`)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "25\n"
     ]
    }
   ],
   "source": [
    "# create the subset\n",
    "tot = cases_per_variant['feature_amplification'] - cases_per_variant['sequence_alteration']\n",
    "print(len(tot))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>gene</th>\n",
       "      <th>case</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Annotated</td>\n",
       "      <td>25</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        gene  case\n",
       "0  Annotated  25  \n",
       "1  BRAF       0   \n",
       "2  EGFR       19  \n",
       "3  ERBB2      6   \n",
       "4  KRAS       0   "
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# create a new Semalytics analysis object\n",
    "a = utils.Analysis(tot, cases_per_gene, cases_per_response, variants_occurrences)\n",
    "\n",
    "# gene variants\n",
    "a.variants"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x122a92470>"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# plot variants distribution\n",
    "a.plot_variants()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>response_type</th>\n",
       "      <th>case</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>response</td>\n",
       "      <td>7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>neutral</td>\n",
       "      <td>9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>progression</td>\n",
       "      <td>9</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  response_type  case\n",
       "0  response      7   \n",
       "1  neutral       9   \n",
       "2  progression   9   "
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# responses\n",
    "a.responses"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, '')"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 360x360 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# plot responses\n",
    "a.plot_responses()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>genes</th>\n",
       "      <th>DRCl_PD</th>\n",
       "      <th>DRCl_SD</th>\n",
       "      <th>DRCl_OR</th>\n",
       "      <th>tot</th>\n",
       "      <th>progression</th>\n",
       "      <th>neutral</th>\n",
       "      <th>response</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>(BRAF,)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>(ERBB2,)</td>\n",
       "      <td>4</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>6</td>\n",
       "      <td>0.666667</td>\n",
       "      <td>0</td>\n",
       "      <td>0.333333</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>(KRAS,)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>(EGFR,)</td>\n",
       "      <td>5</td>\n",
       "      <td>9</td>\n",
       "      <td>5</td>\n",
       "      <td>19</td>\n",
       "      <td>0.263158</td>\n",
       "      <td>0.473684</td>\n",
       "      <td>0.263158</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>(KRAS, EGFR)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>(KRAS, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>(ERBB2, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>(ERBB2, KRAS)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>(ERBB2, EGFR)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>(EGFR, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>(ERBB2, EGFR, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>(ERBB2, KRAS, EGFR)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>(ERBB2, KRAS, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>(KRAS, EGFR, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>(ERBB2, KRAS, EGFR, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                        genes  DRCl_PD  DRCl_SD  DRCl_OR  tot progression  \\\n",
       "0   (BRAF,)                    0        0        0        0                 \n",
       "1   (ERBB2,)                   4        0        2        6    0.666667     \n",
       "2   (KRAS,)                    0        0        0        0                 \n",
       "3   (EGFR,)                    5        9        5        19   0.263158     \n",
       "4   (KRAS, EGFR)               0        0        0        0                 \n",
       "5   (KRAS, BRAF)               0        0        0        0                 \n",
       "6   (ERBB2, BRAF)              0        0        0        0                 \n",
       "7   (ERBB2, KRAS)              0        0        0        0                 \n",
       "8   (ERBB2, EGFR)              0        0        0        0                 \n",
       "9   (EGFR, BRAF)               0        0        0        0                 \n",
       "10  (ERBB2, EGFR, BRAF)        0        0        0        0                 \n",
       "11  (ERBB2, KRAS, EGFR)        0        0        0        0                 \n",
       "12  (ERBB2, KRAS, BRAF)        0        0        0        0                 \n",
       "13  (KRAS, EGFR, BRAF)         0        0        0        0                 \n",
       "14  (ERBB2, KRAS, EGFR, BRAF)  0        0        0        0                 \n",
       "\n",
       "     neutral  response  \n",
       "0                       \n",
       "1   0         0.333333  \n",
       "2                       \n",
       "3   0.473684  0.263158  \n",
       "4                       \n",
       "5                       \n",
       "6                       \n",
       "7                       \n",
       "8                       \n",
       "9                       \n",
       "10                      \n",
       "11                      \n",
       "12                      \n",
       "13                      \n",
       "14                      "
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# variants vs responses\n",
    "a.matching.fillna(\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x122d345f8>"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# plot matching\n",
    "a.plot_matching()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='mseqsubset'></a>\n",
    "###Â Matching `sequence_alteration` only\n",
    "\n",
    "We analyze cases with only 1+ `sequence_alteration` (and with no `feature_amplification`)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "80\n"
     ]
    }
   ],
   "source": [
    "# create the subset\n",
    "tot = cases_per_variant['sequence_alteration'] - cases_per_variant['feature_amplification']\n",
    "print (len(tot))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>gene</th>\n",
       "      <th>case</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Annotated</td>\n",
       "      <td>80</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>12</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>65</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        gene  case\n",
       "0  Annotated  80  \n",
       "1  BRAF       12  \n",
       "2  EGFR       3   \n",
       "3  ERBB2      4   \n",
       "4  KRAS       65  "
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# create a new Semalytics analysis object\n",
    "a = utils.Analysis(tot, cases_per_gene, cases_per_response, variants_occurrences)\n",
    "\n",
    "# gene variants\n",
    "a.variants"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x122f91518>"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# plot variants distribution\n",
    "a.plot_variants()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>response_type</th>\n",
       "      <th>case</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>response</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>neutral</td>\n",
       "      <td>14</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>progression</td>\n",
       "      <td>66</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  response_type  case\n",
       "0  response      0   \n",
       "1  neutral       14  \n",
       "2  progression   66  "
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# responses\n",
    "a.responses"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, '')"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 360x360 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# plot responses\n",
    "a.plot_responses()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>genes</th>\n",
       "      <th>DRCl_PD</th>\n",
       "      <th>DRCl_SD</th>\n",
       "      <th>DRCl_OR</th>\n",
       "      <th>tot</th>\n",
       "      <th>progression</th>\n",
       "      <th>neutral</th>\n",
       "      <th>response</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>(BRAF,)</td>\n",
       "      <td>12</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>12</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>(ERBB2,)</td>\n",
       "      <td>3</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>0.75</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>(KRAS,)</td>\n",
       "      <td>54</td>\n",
       "      <td>11</td>\n",
       "      <td>0</td>\n",
       "      <td>65</td>\n",
       "      <td>0.830769</td>\n",
       "      <td>0.169231</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>(EGFR,)</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>0.333333</td>\n",
       "      <td>0.666667</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>(KRAS, EGFR)</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>(KRAS, BRAF)</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>(ERBB2, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>(ERBB2, KRAS)</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>(ERBB2, EGFR)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>(EGFR, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>(ERBB2, EGFR, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>(ERBB2, KRAS, EGFR)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>(ERBB2, KRAS, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>(KRAS, EGFR, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>(ERBB2, KRAS, EGFR, BRAF)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                        genes  DRCl_PD  DRCl_SD  DRCl_OR  tot progression  \\\n",
       "0   (BRAF,)                    12       0        0        12   1            \n",
       "1   (ERBB2,)                   3        1        0        4    0.75         \n",
       "2   (KRAS,)                    54       11       0        65   0.830769     \n",
       "3   (EGFR,)                    1        2        0        3    0.333333     \n",
       "4   (KRAS, EGFR)               1        0        0        1    1            \n",
       "5   (KRAS, BRAF)               2        0        0        2    1            \n",
       "6   (ERBB2, BRAF)              0        0        0        0                 \n",
       "7   (ERBB2, KRAS)              1        0        0        1    1            \n",
       "8   (ERBB2, EGFR)              0        0        0        0                 \n",
       "9   (EGFR, BRAF)               0        0        0        0                 \n",
       "10  (ERBB2, EGFR, BRAF)        0        0        0        0                 \n",
       "11  (ERBB2, KRAS, EGFR)        0        0        0        0                 \n",
       "12  (ERBB2, KRAS, BRAF)        0        0        0        0                 \n",
       "13  (KRAS, EGFR, BRAF)         0        0        0        0                 \n",
       "14  (ERBB2, KRAS, EGFR, BRAF)  0        0        0        0                 \n",
       "\n",
       "     neutral response  \n",
       "0   0         0        \n",
       "1   0.25      0        \n",
       "2   0.169231  0        \n",
       "3   0.666667  0        \n",
       "4   0         0        \n",
       "5   0         0        \n",
       "6                      \n",
       "7   0         0        \n",
       "8                      \n",
       "9                      \n",
       "10                     \n",
       "11                     \n",
       "12                     \n",
       "13                     \n",
       "14                     "
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# variants vs responses\n",
    "a.matching.fillna(\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x122bfa780>"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# plot matching\n",
    "a.plot_matching()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='wikidata'></a>\n",
    "## Chapter 3 - Querying data with knowlege and Wikidata\n",
    "\n",
    "In this section, we are going to query data with extended knowledge. The platform connects Wikidata by leveraging `owl:sameAs` predicates.\n",
    "\n",
    "The SPARQL endpoint of Semalytics is federated with the Wikidata one (https://query.wikidata.org/sparql).\n",
    "\n",
    "See also this [Web page](https://www.wikidata.org/wiki/User:ProteinBoxBot/SPARQL_Examples#Query_Wikidata_with_SPARQL) for other Wikidata examples related to life sciences. Those queries can be also used for querying local data in Semalytics."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='drugsrole'></a>\n",
    "### Drugs targeting gene products\n",
    "\n",
    "We get chemical compounds (`Q11173`) which physically interacts (`P129`), with a specific role (`P2868`), with products encoded by genes in the investigation panel."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>geneSymbol.value</th>\n",
       "      <th>drugLabel.value</th>\n",
       "      <th>roleLabel.value</th>\n",
       "      <th>gene_productLabel.value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>B-Raf proto-oncogene, serine/threonine kinase</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>B-Raf proto-oncogene, serine/threonine kinase</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>sorafenib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>B-Raf proto-oncogene, serine/threonine kinase</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>vemurafenib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>B-Raf proto-oncogene, serine/threonine kinase</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>icotinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Epidermal growth factor receptor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>dacomitinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Epidermal growth factor receptor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>osimertinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Epidermal growth factor receptor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>gefitinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Epidermal growth factor receptor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>erlotinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Epidermal growth factor receptor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>lapatinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Epidermal growth factor receptor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>5-chloro-N2-(4-(4-(dimethylamino)-1-piperidinyl)-2-methoxyphenyl)-N4-(2-(dimethylphosphinyl)phenyl)-2,4-pyrimidinediamine</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Epidermal growth factor receptor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>afatinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Epidermal growth factor receptor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>canertinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Epidermal growth factor receptor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>neratinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Epidermal growth factor receptor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>vandetanib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Epidermal growth factor receptor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>dacomitinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Erb-b2 receptor tyrosine kinase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>lapatinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Erb-b2 receptor tyrosine kinase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>afatinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Erb-b2 receptor tyrosine kinase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>canertinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Erb-b2 receptor tyrosine kinase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>mubritinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Erb-b2 receptor tyrosine kinase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>neratinib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>Erb-b2 receptor tyrosine kinase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>lonafarnib</td>\n",
       "      <td>enzyme inhibitor</td>\n",
       "      <td>KRAS proto-oncogene, GTPase</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   geneSymbol.value  \\\n",
       "0   BRAF              \n",
       "1   BRAF              \n",
       "2   BRAF              \n",
       "3   BRAF              \n",
       "4   EGFR              \n",
       "5   EGFR              \n",
       "6   EGFR              \n",
       "7   EGFR              \n",
       "8   EGFR              \n",
       "9   EGFR              \n",
       "10  EGFR              \n",
       "11  EGFR              \n",
       "12  EGFR              \n",
       "13  EGFR              \n",
       "14  EGFR              \n",
       "15  ERBB2             \n",
       "16  ERBB2             \n",
       "17  ERBB2             \n",
       "18  ERBB2             \n",
       "19  ERBB2             \n",
       "20  ERBB2             \n",
       "21  KRAS              \n",
       "\n",
       "                                                                                                              drugLabel.value  \\\n",
       "0   dabrafenib                                                                                                                  \n",
       "1   regorafenib                                                                                                                 \n",
       "2   sorafenib                                                                                                                   \n",
       "3   vemurafenib                                                                                                                 \n",
       "4   icotinib                                                                                                                    \n",
       "5   dacomitinib                                                                                                                 \n",
       "6   osimertinib                                                                                                                 \n",
       "7   gefitinib                                                                                                                   \n",
       "8   erlotinib                                                                                                                   \n",
       "9   lapatinib                                                                                                                   \n",
       "10  5-chloro-N2-(4-(4-(dimethylamino)-1-piperidinyl)-2-methoxyphenyl)-N4-(2-(dimethylphosphinyl)phenyl)-2,4-pyrimidinediamine   \n",
       "11  afatinib                                                                                                                    \n",
       "12  canertinib                                                                                                                  \n",
       "13  neratinib                                                                                                                   \n",
       "14  vandetanib                                                                                                                  \n",
       "15  dacomitinib                                                                                                                 \n",
       "16  lapatinib                                                                                                                   \n",
       "17  afatinib                                                                                                                    \n",
       "18  canertinib                                                                                                                  \n",
       "19  mubritinib                                                                                                                  \n",
       "20  neratinib                                                                                                                   \n",
       "21  lonafarnib                                                                                                                  \n",
       "\n",
       "     roleLabel.value                        gene_productLabel.value  \n",
       "0   enzyme inhibitor  B-Raf proto-oncogene, serine/threonine kinase  \n",
       "1   enzyme inhibitor  B-Raf proto-oncogene, serine/threonine kinase  \n",
       "2   enzyme inhibitor  B-Raf proto-oncogene, serine/threonine kinase  \n",
       "3   enzyme inhibitor  B-Raf proto-oncogene, serine/threonine kinase  \n",
       "4   enzyme inhibitor  Epidermal growth factor receptor               \n",
       "5   enzyme inhibitor  Epidermal growth factor receptor               \n",
       "6   enzyme inhibitor  Epidermal growth factor receptor               \n",
       "7   enzyme inhibitor  Epidermal growth factor receptor               \n",
       "8   enzyme inhibitor  Epidermal growth factor receptor               \n",
       "9   enzyme inhibitor  Epidermal growth factor receptor               \n",
       "10  enzyme inhibitor  Epidermal growth factor receptor               \n",
       "11  enzyme inhibitor  Epidermal growth factor receptor               \n",
       "12  enzyme inhibitor  Epidermal growth factor receptor               \n",
       "13  enzyme inhibitor  Epidermal growth factor receptor               \n",
       "14  enzyme inhibitor  Epidermal growth factor receptor               \n",
       "15  enzyme inhibitor  Erb-b2 receptor tyrosine kinase 2              \n",
       "16  enzyme inhibitor  Erb-b2 receptor tyrosine kinase 2              \n",
       "17  enzyme inhibitor  Erb-b2 receptor tyrosine kinase 2              \n",
       "18  enzyme inhibitor  Erb-b2 receptor tyrosine kinase 2              \n",
       "19  enzyme inhibitor  Erb-b2 receptor tyrosine kinase 2              \n",
       "20  enzyme inhibitor  Erb-b2 receptor tyrosine kinase 2              \n",
       "21  enzyme inhibitor  KRAS proto-oncogene, GTPase                    "
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX wd: <http://www.wikidata.org/entity/>\n",
    "PREFIX wdt: <http://www.wikidata.org/prop/direct/>\n",
    "PREFIX pq: <http://www.wikidata.org/prop/qualifier/>\n",
    "PREFIX ps: <http://www.wikidata.org/prop/statement/>\n",
    "PREFIX p: <http://www.wikidata.org/prop/>\n",
    "PREFIX wikibase: <http://wikiba.se/ontology#>\n",
    "PREFIX bd: <http://www.bigdata.com/rdf#>\n",
    "PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n",
    "\n",
    "select ?geneSymbol ?drugLabel ?roleLabel ?gene_productLabel\n",
    "where {\n",
    "\n",
    "    # Wikidata endpoint \n",
    "    SERVICE <https://query.wikidata.org/sparql> {\n",
    "\n",
    "        ?chem p:P129 [\n",
    "            ps:P129 ?gene_product ;\n",
    "            pq:P2868 ?role ] .\n",
    "        ?chem wdt:P31 wd:Q11173 .\n",
    "        ?gene_product wdt:P702 ?gene .\n",
    "\n",
    "        SERVICE wikibase:label { \n",
    "            bd:serviceParam wikibase:language \"en\" . \n",
    "            ?chem rdfs:label ?drugLabel .\n",
    "            ?gene_product rdfs:label ?gene_productLabel .\n",
    "            ?role rdfs:label ?roleLabel .\n",
    "        }\n",
    "    }\n",
    "    \n",
    "    #local data\n",
    "    ?gene :symbol ?geneSymbol\n",
    "    VALUES ?geneSymbol {'KRAS' 'EGFR' 'BRAF' 'ERBB2'}\n",
    "}\n",
    "order by ?geneSymbol\n",
    "\"\"\"\n",
    "\n",
    "# get data\n",
    "result_table = utils.query(SEMALYTICS_ENDPOINT, my_query)\n",
    "\n",
    "# there you go!\n",
    "result_table[['geneSymbol.value', 'drugLabel.value', 'roleLabel.value', 'gene_productLabel.value']]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='dabrafenib'></a>\n",
    "### Drug information: dabrafenib\n",
    "\n",
    "Now we get from Wikidata the  **chemical formula** (P274) of one of those drug: the **dabrafenib**..."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>chem.type</th>\n",
       "      <th>chem.value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>literal</td>\n",
       "      <td>Câ‚‚â‚ƒHâ‚‚â‚€Fâ‚ƒNâ‚…Oâ‚‚Sâ‚‚</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  chem.type      chem.value\n",
       "0  literal   Câ‚‚â‚ƒHâ‚‚â‚€Fâ‚ƒNâ‚…Oâ‚‚Sâ‚‚"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "my_query = \"\"\"\n",
    "PREFIX wd: <http://www.wikidata.org/entity/>\n",
    "PREFIX wdt: <http://www.wikidata.org/prop/direct/>\n",
    "SELECT *\n",
    "WHERE \n",
    "{\n",
    "  wd:Q3011604 wdt:P274 ?chem .\n",
    "}\n",
    "\"\"\"\n",
    "\n",
    "# get data\n",
    "result_table = utils.query(WIKIDATA_ENDPOINT, my_query)\n",
    "\n",
    "result_table"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "...as well as its **chemical structure** (`P117`)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/svg+xml": [
       "<svg enable-background=\"new 0 0 604.459 381.203\" height=\"381.203px\" id=\"Ð¡Ð»Ð¾Ð¹_1\" version=\"1.1\" viewBox=\"0 0 604.459 381.203\" width=\"604.459px\" x=\"0px\" xml:space=\"preserve\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" y=\"0px\">\n",
       "<g>\n",
       "\t<rect height=\"2.398\" width=\"27.949\" x=\"443.15\" y=\"105.905\"/>\n",
       "\t<rect height=\"2.398\" transform=\"matrix(-0.809 -0.5878 0.5878 -0.809 685.7554 542.924)\" width=\"45.628\" x=\"408.264\" y=\"158.86\"/>\n",
       "\t<polygon points=\"486.873,130.754 489.158,130.012 478.414,96.947 511.206,51.815 556.833,84.965 558.244,83.023 512.617,49.873    545.767,4.244 543.826,2.832 510.674,48.462 465.044,15.311 463.634,17.252 509.264,50.404 476.474,95.537 437.162,95.537    437.162,97.938 476.212,97.938  \"/>\n",
       "\t<rect height=\"2.401\" transform=\"matrix(-0.866 -0.5 0.5 -0.866 512.8055 487.1992)\" width=\"45.629\" x=\"298.861\" y=\"173.696\"/>\n",
       "\t<rect height=\"26.202\" transform=\"matrix(0.4998 -0.8661 0.8661 0.4998 3.4062 528.8983)\" width=\"2.399\" x=\"458.431\" y=\"248.399\"/>\n",
       "\t\n",
       "\t\t<rect height=\"45.628\" transform=\"matrix(-0.4998 -0.8661 0.8661 -0.4998 271.6896 643.5781)\" width=\"2.399\" x=\"320.476\" y=\"220.526\"/>\n",
       "\t<polygon points=\"499.365,292.004 496.966,292.004 496.966,328.68 464.505,347.426 465.705,349.504 498.167,330.757 530.63,349.504    531.826,347.426 499.365,328.678  \"/>\n",
       "\t<rect height=\"45.625\" width=\"2.402\" x=\"407.566\" y=\"277.762\"/>\n",
       "\t<rect height=\"45.629\" width=\"2.4\" x=\"261.203\" y=\"186.305\"/>\n",
       "\t\n",
       "\t\t<rect height=\"26.205\" transform=\"matrix(0.4998 0.8661 -0.8661 0.4998 524.083 -247.6412)\" width=\"2.399\" x=\"475.253\" y=\"316.835\"/>\n",
       "\t<rect height=\"28.615\" transform=\"matrix(0.4998 0.8661 -0.8661 0.4998 232.3437 -65.565)\" width=\"2.399\" x=\"171.739\" y=\"154.077\"/>\n",
       "\t<polygon points=\"150.417,205.879 158.117,219.215 160.197,218.02 152.498,204.684  \"/>\n",
       "\t<polygon points=\"169.175,212.832 161.476,199.496 159.398,200.699 167.097,214.035  \"/>\n",
       "\t<rect height=\"2.399\" transform=\"matrix(-0.5 -0.866 0.866 -0.5 49.4045 351.2899)\" width=\"15.399\" x=\"118.413\" y=\"160.183\"/>\n",
       "\t\n",
       "\t\t<rect height=\"15.4\" transform=\"matrix(-0.8663 0.4995 -0.4995 -0.8663 330.1415 224.0467)\" width=\"2.401\" x=\"133.891\" y=\"148.499\"/>\n",
       "\t<rect height=\"2.403\" transform=\"matrix(0.866 0.5001 -0.5001 0.866 111.5435 -8.8372)\" width=\"45.628\" x=\"49.446\" y=\"202.498\"/>\n",
       "\t<rect height=\"45.625\" width=\"2.398\" x=\"11.789\" y=\"215.105\"/>\n",
       "\t<polygon points=\"92.617,261.77 91.417,259.691 51.904,282.504 53.103,284.59  \"/>\n",
       "\t<path d=\"M103.585,209.813l27.148-15.677l-1.199-2.078l-27.148,15.677l-48.684-28.11v-36.678h-2.4v36.679l-47.55,27.457l0-0.001   l-1.73,1l-0.602,0.344v0.695v2v53.594v2v0.695l0.602,0.352l1.73,1l0-0.001l46.419,26.798l0,0l1.732,1l0.6,0.344l0.6-0.344   l49.283-28.458l34.082,19.685l1.199-2.086l-34.082-19.678V209.813z M3.82,211.121v-1.307l48.684-28.111l48.682,28.109v56.211   l-48.682,28.11L3.82,266.022v-1.308V211.121z\"/>\n",
       "\t<polygon points=\"411.837,88.064 426.876,110.564 430.763,110.564 430.763,81.932 427.13,81.932 427.13,104.412 412.091,81.932    408.205,81.932 408.205,110.564 411.837,110.564  \"/>\n",
       "\t<path d=\"M499.345,162.035c-1.105,0.43-2.383,0.645-3.828,0.645c-1.629,0-3.09-0.283-4.395-0.85   c-1.301-0.566-2.262-1.309-2.879-2.227c-0.621-0.918-1.012-2.092-1.184-3.525l-3.574,0.312c0.051,1.914,0.578,3.631,1.574,5.146   c0.996,1.518,2.367,2.654,4.121,3.408c1.75,0.756,3.922,1.133,6.512,1.133c2.047,0,3.883-0.373,5.52-1.123   c1.633-0.748,2.887-1.797,3.758-3.145s1.309-2.783,1.309-4.307c0-1.535-0.398-2.893-1.191-4.072   c-0.793-1.178-2.023-2.15-3.691-2.92c-1.145-0.52-3.258-1.129-6.336-1.826c-3.082-0.695-4.984-1.377-5.715-2.041   c-0.742-0.664-1.113-1.51-1.113-2.539c0-1.184,0.523-2.197,1.574-3.037c1.047-0.84,2.715-1.26,5.008-1.26   c2.199,0,3.863,0.463,4.992,1.387c1.125,0.926,1.785,2.293,1.98,4.102l3.633-0.273c-0.062-1.68-0.531-3.184-1.406-4.512   c-0.871-1.328-2.117-2.334-3.738-3.018s-3.496-1.025-5.617-1.025c-1.926,0-3.676,0.326-5.254,0.977   c-1.574,0.652-2.773,1.605-3.594,2.861c-0.82,1.258-1.23,2.607-1.23,4.053c0,1.316,0.336,2.504,1.008,3.564   c0.668,1.062,1.688,1.951,3.055,2.666c1.055,0.561,2.898,1.156,5.527,1.787c2.633,0.633,4.328,1.098,5.098,1.396   c1.199,0.457,2.059,1.02,2.578,1.689c0.52,0.672,0.781,1.455,0.781,2.354c0,0.887-0.27,1.703-0.809,2.451   C501.275,161.018,500.451,161.605,499.345,162.035z\"/>\n",
       "\t<polygon points=\"490.521,263.105 505.56,285.605 509.447,285.605 509.447,256.973 505.814,256.973 505.814,279.449    490.775,256.973 486.888,256.973 486.888,285.605 490.521,285.605  \"/>\n",
       "\t<polygon points=\"296.048,94.738 309.486,94.738 309.486,91.359 296.048,91.359 296.048,82.492 311.576,82.492 311.576,79.113    292.259,79.113 292.259,107.746 296.048,107.746  \"/>\n",
       "\t<path d=\"M399.599,327.371v-53.594v-1.306l48.686-28.113l32.459,18.747l1.199-2.086l-32.461-18.741v-56.29l29.531-21.459   l-1.41-1.939l-29.32,21.301l-45.188-32.829l11.06-34.039l-2.281-0.742l-11.186,34.426L351.8,178.933l-48.682-28.107v-36.679h-2.4   v36.678l-48.684,28.108l-32.461-18.742l-1.199,2.078l32.461,18.742v54.907v2l-0.002,0.695l0.602,0.344l49.883,28.797l0.6,0.352   l0.6-0.352l1.732-1l0,0l46.42-26.798v0.001l1.73-1l0.602-0.344v-0.695v-2V181.01l48.608-28.063l45.474,33.041v56.293   l-47.551,27.458v-0.001l-1.73,1l-0.602,0.344v0.695v2v53.594v2v0.695l0.602,0.352l1.73,1v-0.001l31.328,18.087l1.199-2.078   l-32.461-18.748V327.371z M401.684,151.517l-0.001,0.001l-0.001-0.002L401.684,151.517z M301.917,151.519L301.917,151.519   L301.917,151.519L301.917,151.519z M350.599,237.227l-48.681,28.103l-1.131-0.653l0,0.001l-46.419-26.798l0,0l-1.131-0.652v-1.309   V181.01l48.682-28.105l48.682,28.105v54.908V237.227z\"/>\n",
       "\t<polygon points=\"209.798,159.193 194.759,136.713 190.873,136.713 190.873,165.346 194.505,165.346 194.505,142.846    209.544,165.346 213.431,165.346 213.431,136.713 209.798,136.713  \"/>\n",
       "\t<polygon points=\"194.71,119.217 209.593,119.217 209.593,132.713 213.382,132.713 213.382,104.08 209.593,104.08 209.593,115.838    194.71,115.838 194.71,104.08 190.921,104.08 190.921,132.713 194.71,132.713  \"/>\n",
       "\t<polygon points=\"555.697,365.848 540.658,343.371 536.771,343.371 536.771,372.004 540.404,372.004 540.404,349.504    555.443,372.004 559.33,372.004 559.33,343.371 555.697,343.371  \"/>\n",
       "\t<polygon points=\"582.001,355.129 567.119,355.129 567.119,343.371 563.33,343.371 563.33,372.004 567.119,372.004 567.119,358.504    582.001,358.504 582.001,372.004 585.791,372.004 585.791,343.371 582.001,343.371  \"/>\n",
       "\t<path d=\"M593.208,376.004c0.273-0.445,0.621-0.891,1.039-1.336c0.422-0.438,1.367-1.281,2.844-2.523   c1.77-1.492,3.035-2.672,3.797-3.523c0.758-0.859,1.305-1.672,1.633-2.445c0.328-0.781,0.492-1.57,0.492-2.367   c0-1.578-0.562-2.898-1.684-3.969c-1.121-1.062-2.641-1.594-4.566-1.594c-1.902,0-3.422,0.492-4.551,1.477   c-1.129,0.992-1.781,2.43-1.957,4.32l2.531,0.258c0.008-1.258,0.367-2.242,1.078-2.953s1.66-1.07,2.844-1.07   c1.121,0,2.031,0.336,2.73,1.008c0.695,0.672,1.043,1.492,1.043,2.469c0,0.93-0.383,1.914-1.148,2.961   c-0.766,1.039-2.234,2.453-4.414,4.242c-1.402,1.148-2.477,2.164-3.219,3.039s-1.285,1.758-1.621,2.664   c-0.211,0.547-0.305,1.117-0.289,1.711h13.25v-2.367H593.208z\"/>\n",
       "\t<polygon points=\"455.931,365.848 440.892,343.371 437.005,343.371 437.005,372.004 440.638,372.004 440.638,349.504    455.677,372.004 459.564,372.004 459.564,343.371 455.931,343.371  \"/>\n",
       "\t<path d=\"M151.669,197.754c1.633-0.75,2.887-1.797,3.76-3.141c0.871-1.352,1.309-2.785,1.309-4.309c0-1.537-0.398-2.895-1.191-4.072   c-0.795-1.178-2.025-2.152-3.691-2.92c-1.146-0.521-3.26-1.129-6.338-1.826c-3.08-0.697-4.984-1.377-5.713-2.041   c-0.742-0.664-1.113-1.51-1.113-2.539c0-1.186,0.523-2.197,1.572-3.037c1.047-0.84,2.717-1.26,5.01-1.26   c2.199,0,3.863,0.463,4.99,1.387c1.125,0.924,1.787,2.291,1.982,4.102l3.633-0.273c-0.066-1.68-0.535-3.184-1.406-4.512   c-0.873-1.328-2.119-2.334-3.74-3.018s-3.494-1.025-5.615-1.025c-1.928,0-3.68,0.326-5.254,0.977   c-1.576,0.65-2.773,1.605-3.594,2.861s-1.23,2.607-1.23,4.053c0,1.314,0.334,2.504,1.006,3.564c0.67,1.061,1.689,1.949,3.057,2.666   c1.055,0.561,2.896,1.156,5.527,1.787c2.629,0.631,4.328,1.098,5.098,1.396c1.197,0.455,2.057,1.02,2.578,1.689   c0.52,0.67,0.781,1.455,0.781,2.354c0,0.887-0.271,1.703-0.811,2.449c-0.541,0.75-1.365,1.344-2.471,1.773   c-1.107,0.43-2.383,0.641-3.828,0.641c-1.629,0-3.094-0.281-4.395-0.852c-1.303-0.562-2.264-1.305-2.881-2.227   c-0.619-0.914-1.014-2.092-1.182-3.523l-3.574,0.312c0.051,1.914,0.576,3.629,1.572,5.148c0.996,1.516,2.369,2.648,4.121,3.406   c1.75,0.758,3.922,1.133,6.514,1.133C148.195,198.879,150.035,198.504,151.669,197.754z\"/>\n",
       "\t<path d=\"M181.308,221.035c-2.121-1.258-4.504-1.891-7.148-1.891c-4.035,0-7.33,1.344-9.883,4.031   c-2.551,2.688-3.828,6.406-3.828,11.164c0,2.508,0.547,4.891,1.641,7.148c1.094,2.25,2.703,4.031,4.824,5.328   c2.123,1.305,4.531,1.953,7.227,1.953c2.488,0,4.805-0.586,6.953-1.766s3.809-2.914,4.98-5.203   c1.172-2.297,1.758-4.891,1.758-7.797c0-2.859-0.557-5.422-1.67-7.68C185.048,224.059,183.431,222.301,181.308,221.035z    M181.162,242.52c-1.842,2.008-4.189,3.008-7.041,3.008c-2.799,0-5.127-0.992-6.982-2.977s-2.783-4.703-2.783-8.156   c0-4.305,0.967-7.383,2.9-9.227s4.242-2.766,6.924-2.766c1.889,0,3.592,0.484,5.107,1.438c1.518,0.961,2.67,2.305,3.457,4.047   c0.789,1.734,1.182,3.766,1.182,6.102C183.925,237.668,183.005,240.52,181.162,242.52z\"/>\n",
       "\t<path d=\"M109.314,147.053c2.123,1.303,4.531,1.953,7.227,1.953c2.486,0,4.805-0.59,6.953-1.768s3.809-2.914,4.98-5.205   s1.758-4.889,1.758-7.793c0-2.865-0.557-5.426-1.67-7.686s-2.73-4.02-4.854-5.283s-4.506-1.895-7.148-1.895   c-4.037,0-7.33,1.344-9.883,4.033s-3.828,6.41-3.828,11.162c0,2.514,0.547,4.896,1.641,7.148S107.191,145.75,109.314,147.053z    M109.656,125.402c1.934-1.842,4.242-2.764,6.924-2.764c1.889,0,3.59,0.479,5.107,1.436s2.67,2.305,3.457,4.043   s1.182,3.773,1.182,6.104c0,3.686-0.922,6.529-2.764,8.535s-4.189,3.008-7.041,3.008c-2.799,0-5.127-0.992-6.982-2.979   s-2.783-4.703-2.783-8.154C106.755,130.32,107.722,127.244,109.656,125.402z\"/>\n",
       "\t<polygon points=\"46.634,123.539 60.072,123.539 60.072,120.16 46.634,120.16 46.634,111.293 62.162,111.293 62.162,107.914    42.845,107.914 42.845,136.547 46.634,136.547  \"/>\n",
       "\t<polygon points=\"142.611,309.348 146.4,309.348 146.4,296.34 159.837,296.34 159.837,292.957 146.4,292.957 146.4,284.09    161.927,284.09 161.927,280.715 142.611,280.715  \"/>\n",
       "</g>\n",
       "</svg>"
      ],
      "text/plain": [
       "<IPython.core.display.SVG object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "live rendering from Wikidata of http://commons.wikimedia.org/wiki/Special:FilePath/Dabrafenib.svg\n"
     ]
    }
   ],
   "source": [
    "my_query = \"\"\"\n",
    "PREFIX wd: <http://www.wikidata.org/entity/>\n",
    "PREFIX wdt: <http://www.wikidata.org/prop/direct/>\n",
    "SELECT *\n",
    "WHERE \n",
    "{\n",
    "  wd:Q3011604 wdt:P117 ?struct .\n",
    "}\n",
    "\"\"\"\n",
    "\n",
    "# get data\n",
    "result_table = utils.query(WIKIDATA_ENDPOINT, my_query)\n",
    "\n",
    "display(SVG(url=result_table['struct.value'][0]))\n",
    "\n",
    "print (f'live rendering from Wikidata of {result_table[\"struct.value\"][0]}')\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Finally, we get **medical conditions treated** (P2175), relative data source (1) and information retrieval date.\n",
    "\n",
    "_(1) \"dataset containing drug indications extracted from the FDA Adverse Event Reporting System\"_"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>medical_conditionLabel.value</th>\n",
       "      <th>referenceLabel.value</th>\n",
       "      <th>date.value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Drug Indications Extracted from FAERS</td>\n",
       "      <td>2018-10-02T00:00:00Z</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>skin cancer</td>\n",
       "      <td>Drug Indications Extracted from FAERS</td>\n",
       "      <td>2018-10-02T00:00:00Z</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>metastatic melanoma</td>\n",
       "      <td>Drug Indications Extracted from FAERS</td>\n",
       "      <td>2018-10-02T00:00:00Z</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>melanoma</td>\n",
       "      <td>Drug Indications Extracted from FAERS</td>\n",
       "      <td>2018-10-02T00:00:00Z</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    medical_conditionLabel.value                   referenceLabel.value  \\\n",
       "0  non-small-cell lung carcinoma  Drug Indications Extracted from FAERS   \n",
       "1  skin cancer                    Drug Indications Extracted from FAERS   \n",
       "2  metastatic melanoma            Drug Indications Extracted from FAERS   \n",
       "3  melanoma                       Drug Indications Extracted from FAERS   \n",
       "\n",
       "             date.value  \n",
       "0  2018-10-02T00:00:00Z  \n",
       "1  2018-10-02T00:00:00Z  \n",
       "2  2018-10-02T00:00:00Z  \n",
       "3  2018-10-02T00:00:00Z  "
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "my_query = \"\"\"\n",
    "SELECT ?medical_conditionLabel ?referenceLabel ?date\n",
    "WHERE \n",
    "{\n",
    "  wd:Q3011604 p:P2175 [\n",
    "    ps:P2175 ?medical_condition ;\n",
    "   prov:wasDerivedFrom ?source \n",
    "  ].\n",
    "  ?source pr:P248 ?reference ;\n",
    "          pr:P813 ?date\n",
    "  SERVICE wikibase:label { bd:serviceParam wikibase:language \"en\". }\n",
    "}\n",
    "\"\"\"\n",
    "\n",
    "# get data\n",
    "result_table = utils.query(WIKIDATA_ENDPOINT, my_query)\n",
    "\n",
    "# there you go\n",
    "result_table[['medical_conditionLabel.value', 'referenceLabel.value', 'date.value']]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='queryinnvar'></a>\n",
    "### Querying variants\n",
    "\n",
    "We can also query only cases with variants mapped to Wikidata. Those are entry points for knowledge enrichment. The column `alt_p.value` represents the type of `point_mutation`."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>case.value</th>\n",
       "      <th>variant.value</th>\n",
       "      <th>geneSymbol.value</th>\n",
       "      <th>alt_p.value</th>\n",
       "      <th>annotation_Type.value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>CRC0354</td>\n",
       "      <td>Q29938363</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>Q61H</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>CRC0139</td>\n",
       "      <td>Q29938363</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>Q61H</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>CRC0438</td>\n",
       "      <td>Q29938368</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>Q61K</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>CRC0024</td>\n",
       "      <td>Q32948338</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13C</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>CRC0315</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>CRC0127</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>CRC0071</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>CRC0237</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>CRC0018</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>CRC0019</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>CRC0479</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>CRC0504</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>CRC0714</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>CRC0149</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>CRC0082</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>CRC0156</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>CRC0481</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>CRC0028</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>CRC0027</td>\n",
       "      <td>Q28371015</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G13D</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>CRC0471</td>\n",
       "      <td>Q29938370</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G12S</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>CRC0312</td>\n",
       "      <td>Q29938370</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G12S</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>CRC0449</td>\n",
       "      <td>Q29938641</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>Q61P</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>CRC0180</td>\n",
       "      <td>Q28371486</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G12R</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>CRC0128</td>\n",
       "      <td>Q28371011</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G12C</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>CRC0382</td>\n",
       "      <td>Q28371011</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G12C</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>CRC0068</td>\n",
       "      <td>Q28371011</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G12C</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>CRC0094</td>\n",
       "      <td>Q28371011</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G12C</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>CRC0167</td>\n",
       "      <td>Q28371011</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G12C</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>CRC0143</td>\n",
       "      <td>Q28371011</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G12C</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>CRC0073</td>\n",
       "      <td>Q28371011</td>\n",
       "      <td>KRAS</td>\n",
       "      <td>G12C</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>CRC0362</td>\n",
       "      <td>Q28444964</td>\n",
       "      <td>EGFR</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>CRC0327</td>\n",
       "      <td>Q28444964</td>\n",
       "      <td>EGFR</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>CRC0328</td>\n",
       "      <td>Q28444964</td>\n",
       "      <td>EGFR</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>CRC0449</td>\n",
       "      <td>Q28444964</td>\n",
       "      <td>EGFR</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>CRC0481</td>\n",
       "      <td>Q28444964</td>\n",
       "      <td>EGFR</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>CRC0527</td>\n",
       "      <td>Q28444964</td>\n",
       "      <td>EGFR</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>93</th>\n",
       "      <td>CRC0537</td>\n",
       "      <td>Q28444964</td>\n",
       "      <td>EGFR</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>CRC0542</td>\n",
       "      <td>Q28444964</td>\n",
       "      <td>EGFR</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>CRC1278</td>\n",
       "      <td>Q28444964</td>\n",
       "      <td>EGFR</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>CRC0480</td>\n",
       "      <td>Q21851559</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>V600E</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>CRC0528</td>\n",
       "      <td>Q21851559</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>V600E</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>CRC0323</td>\n",
       "      <td>Q21851559</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>V600E</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>CRC0118</td>\n",
       "      <td>Q21851559</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>V600E</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>100</th>\n",
       "      <td>CRC0106</td>\n",
       "      <td>Q21851559</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>V600E</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>101</th>\n",
       "      <td>CRC0484</td>\n",
       "      <td>Q21851559</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>V600E</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>102</th>\n",
       "      <td>CRC0079</td>\n",
       "      <td>Q21851559</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>V600E</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>103</th>\n",
       "      <td>CRC1138</td>\n",
       "      <td>Q28371540</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>K601E</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>104</th>\n",
       "      <td>CRC1063</td>\n",
       "      <td>Q28371540</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>K601E</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>105</th>\n",
       "      <td>CRC0150</td>\n",
       "      <td>Q50092868</td>\n",
       "      <td>BRAF</td>\n",
       "      <td>G466V</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>106</th>\n",
       "      <td>CRC0504</td>\n",
       "      <td>Q28370981</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td>R678Q</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>107</th>\n",
       "      <td>CRC0126</td>\n",
       "      <td>Q28370984</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td>V777L</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>108</th>\n",
       "      <td>CRC0131</td>\n",
       "      <td>Q28370984</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td>V777L</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>109</th>\n",
       "      <td>CRC0124</td>\n",
       "      <td>Q29938313</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td>H878Y</td>\n",
       "      <td>sequence_alteration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>110</th>\n",
       "      <td>CRC0124</td>\n",
       "      <td>Q27908387</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>111</th>\n",
       "      <td>CRC0080</td>\n",
       "      <td>Q27908387</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>112</th>\n",
       "      <td>CRC0185</td>\n",
       "      <td>Q27908387</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>113</th>\n",
       "      <td>CRC0186</td>\n",
       "      <td>Q27908387</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>114</th>\n",
       "      <td>CRC0112</td>\n",
       "      <td>Q27908387</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>115</th>\n",
       "      <td>CRC0729</td>\n",
       "      <td>Q27908387</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>116</th>\n",
       "      <td>CRC0743</td>\n",
       "      <td>Q27908387</td>\n",
       "      <td>ERBB2</td>\n",
       "      <td></td>\n",
       "      <td>feature_amplification</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>117 rows Ã— 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    case.value variant.value geneSymbol.value alt_p.value  \\\n",
       "0    CRC0354    Q29938363     KRAS             Q61H         \n",
       "1    CRC0139    Q29938363     KRAS             Q61H         \n",
       "2    CRC0438    Q29938368     KRAS             Q61K         \n",
       "3    CRC0024    Q32948338     KRAS             G13C         \n",
       "4    CRC0315    Q28371015     KRAS             G13D         \n",
       "5    CRC0127    Q28371015     KRAS             G13D         \n",
       "6    CRC0071    Q28371015     KRAS             G13D         \n",
       "7    CRC0237    Q28371015     KRAS             G13D         \n",
       "8    CRC0018    Q28371015     KRAS             G13D         \n",
       "9    CRC0019    Q28371015     KRAS             G13D         \n",
       "10   CRC0479    Q28371015     KRAS             G13D         \n",
       "11   CRC0504    Q28371015     KRAS             G13D         \n",
       "12   CRC0714    Q28371015     KRAS             G13D         \n",
       "13   CRC0149    Q28371015     KRAS             G13D         \n",
       "14   CRC0082    Q28371015     KRAS             G13D         \n",
       "15   CRC0156    Q28371015     KRAS             G13D         \n",
       "16   CRC0481    Q28371015     KRAS             G13D         \n",
       "17   CRC0028    Q28371015     KRAS             G13D         \n",
       "18   CRC0027    Q28371015     KRAS             G13D         \n",
       "19   CRC0471    Q29938370     KRAS             G12S         \n",
       "20   CRC0312    Q29938370     KRAS             G12S         \n",
       "21   CRC0449    Q29938641     KRAS             Q61P         \n",
       "22   CRC0180    Q28371486     KRAS             G12R         \n",
       "23   CRC0128    Q28371011     KRAS             G12C         \n",
       "24   CRC0382    Q28371011     KRAS             G12C         \n",
       "25   CRC0068    Q28371011     KRAS             G12C         \n",
       "26   CRC0094    Q28371011     KRAS             G12C         \n",
       "27   CRC0167    Q28371011     KRAS             G12C         \n",
       "28   CRC0143    Q28371011     KRAS             G12C         \n",
       "29   CRC0073    Q28371011     KRAS             G12C         \n",
       "..       ...          ...      ...              ...         \n",
       "87   CRC0362    Q28444964     EGFR                          \n",
       "88   CRC0327    Q28444964     EGFR                          \n",
       "89   CRC0328    Q28444964     EGFR                          \n",
       "90   CRC0449    Q28444964     EGFR                          \n",
       "91   CRC0481    Q28444964     EGFR                          \n",
       "92   CRC0527    Q28444964     EGFR                          \n",
       "93   CRC0537    Q28444964     EGFR                          \n",
       "94   CRC0542    Q28444964     EGFR                          \n",
       "95   CRC1278    Q28444964     EGFR                          \n",
       "96   CRC0480    Q21851559     BRAF             V600E        \n",
       "97   CRC0528    Q21851559     BRAF             V600E        \n",
       "98   CRC0323    Q21851559     BRAF             V600E        \n",
       "99   CRC0118    Q21851559     BRAF             V600E        \n",
       "100  CRC0106    Q21851559     BRAF             V600E        \n",
       "101  CRC0484    Q21851559     BRAF             V600E        \n",
       "102  CRC0079    Q21851559     BRAF             V600E        \n",
       "103  CRC1138    Q28371540     BRAF             K601E        \n",
       "104  CRC1063    Q28371540     BRAF             K601E        \n",
       "105  CRC0150    Q50092868     BRAF             G466V        \n",
       "106  CRC0504    Q28370981     ERBB2            R678Q        \n",
       "107  CRC0126    Q28370984     ERBB2            V777L        \n",
       "108  CRC0131    Q28370984     ERBB2            V777L        \n",
       "109  CRC0124    Q29938313     ERBB2            H878Y        \n",
       "110  CRC0124    Q27908387     ERBB2                         \n",
       "111  CRC0080    Q27908387     ERBB2                         \n",
       "112  CRC0185    Q27908387     ERBB2                         \n",
       "113  CRC0186    Q27908387     ERBB2                         \n",
       "114  CRC0112    Q27908387     ERBB2                         \n",
       "115  CRC0729    Q27908387     ERBB2                         \n",
       "116  CRC0743    Q27908387     ERBB2                         \n",
       "\n",
       "     annotation_Type.value  \n",
       "0    sequence_alteration    \n",
       "1    sequence_alteration    \n",
       "2    sequence_alteration    \n",
       "3    sequence_alteration    \n",
       "4    sequence_alteration    \n",
       "5    sequence_alteration    \n",
       "6    sequence_alteration    \n",
       "7    sequence_alteration    \n",
       "8    sequence_alteration    \n",
       "9    sequence_alteration    \n",
       "10   sequence_alteration    \n",
       "11   sequence_alteration    \n",
       "12   sequence_alteration    \n",
       "13   sequence_alteration    \n",
       "14   sequence_alteration    \n",
       "15   sequence_alteration    \n",
       "16   sequence_alteration    \n",
       "17   sequence_alteration    \n",
       "18   sequence_alteration    \n",
       "19   sequence_alteration    \n",
       "20   sequence_alteration    \n",
       "21   sequence_alteration    \n",
       "22   sequence_alteration    \n",
       "23   sequence_alteration    \n",
       "24   sequence_alteration    \n",
       "25   sequence_alteration    \n",
       "26   sequence_alteration    \n",
       "27   sequence_alteration    \n",
       "28   sequence_alteration    \n",
       "29   sequence_alteration    \n",
       "..                   ...    \n",
       "87   feature_amplification  \n",
       "88   feature_amplification  \n",
       "89   feature_amplification  \n",
       "90   feature_amplification  \n",
       "91   feature_amplification  \n",
       "92   feature_amplification  \n",
       "93   feature_amplification  \n",
       "94   feature_amplification  \n",
       "95   feature_amplification  \n",
       "96   sequence_alteration    \n",
       "97   sequence_alteration    \n",
       "98   sequence_alteration    \n",
       "99   sequence_alteration    \n",
       "100  sequence_alteration    \n",
       "101  sequence_alteration    \n",
       "102  sequence_alteration    \n",
       "103  sequence_alteration    \n",
       "104  sequence_alteration    \n",
       "105  sequence_alteration    \n",
       "106  sequence_alteration    \n",
       "107  sequence_alteration    \n",
       "108  sequence_alteration    \n",
       "109  sequence_alteration    \n",
       "110  feature_amplification  \n",
       "111  feature_amplification  \n",
       "112  feature_amplification  \n",
       "113  feature_amplification  \n",
       "114  feature_amplification  \n",
       "115  feature_amplification  \n",
       "116  feature_amplification  \n",
       "\n",
       "[117 rows x 5 columns]"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX wdt: <http://www.wikidata.org/prop/direct/>\n",
    "PREFIX owl: <http://www.w3.org/2002/07/owl#>\n",
    "select distinct ?case ?variant ?geneSymbol ?alt_p ?annotation_Type\n",
    "\n",
    "where {\n",
    "\n",
    "    SERVICE <https://query.wikidata.org/sparql> {\n",
    "        ?variant wdt:P3329 ?id .\n",
    "    }\n",
    "\n",
    "\n",
    "    ?case a :Case ;\n",
    "          :hasDescendant ?mouse ;\n",
    "          :hasDescendant ?node .\n",
    "    ?mouse a :Biomouse ;\n",
    "           :has_annotation ?ann .\n",
    "    ?ann :has_reference ?ref .\n",
    "    ?ref a :drug_response .\n",
    "    ?node :has_annotation ?ann2 .\n",
    "    ?ann2 :has_reference ?variant .\n",
    "    ?gene :has_variant ?variant.\n",
    "    OPTIONAL {?variant :alt_p ?alt_p }\n",
    "    ?gene :symbol ?geneSymbol\n",
    "    VALUES ?geneSymbol {'KRAS' 'EGFR' 'BRAF' 'ERBB2'}\n",
    "    ?variant a ?annotation_Type.\n",
    "    VALUES ?annotation_Type { :sequence_alteration :feature_amplification }\n",
    "}\n",
    "\"\"\"\n",
    "\n",
    "# get data\n",
    "result_table = utils.query(SEMALYTICS_ENDPOINT, my_query)\n",
    "\n",
    "# filter URIs prefixes\n",
    "utils.filter_prefixes(result_table)\n",
    "\n",
    "# there you go\n",
    "result_table[['case.value', 'variant.value', 'geneSymbol.value', 'alt_p.value', 'annotation_Type.value']].fillna(\"\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='pos'></a>\n",
    "## Positive therapeutic predictors\n",
    "\n",
    "We can use the **variants occurrences** annotated in the local database for querying **associated positive response predictions** to drugs. Moreover, we retrieve also the scientific article from where the evidence comes and the relative medical condition treated."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>geneSymbol.value</th>\n",
       "      <th>variantLabel.value</th>\n",
       "      <th>treatmentLabel.value</th>\n",
       "      <th>diseaseLabel.value</th>\n",
       "      <th>referenceLabel.value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF G466V</td>\n",
       "      <td>vemurafenib</td>\n",
       "      <td>cancer</td>\n",
       "      <td>Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF K601E</td>\n",
       "      <td>vemurafenib</td>\n",
       "      <td>skin melanoma</td>\n",
       "      <td>BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF K601E</td>\n",
       "      <td>trametinib</td>\n",
       "      <td>skin melanoma</td>\n",
       "      <td>BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>cobimetinib fumarate</td>\n",
       "      <td>cancer</td>\n",
       "      <td>Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>vemurafenib</td>\n",
       "      <td>ovarian cancer</td>\n",
       "      <td>Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>Dabrafenib / Trametinib combination therapy</td>\n",
       "      <td>melanoma</td>\n",
       "      <td>Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>vemurafenib</td>\n",
       "      <td>melanoma</td>\n",
       "      <td>Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>Dabrafenib / Trametinib combination therapy</td>\n",
       "      <td>melanoma</td>\n",
       "      <td>Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>vemurafenib / cobimetinib fumarate combination therapy</td>\n",
       "      <td>melanoma</td>\n",
       "      <td>Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>pictilisib</td>\n",
       "      <td>melanoma</td>\n",
       "      <td>First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>selumetinib / dactolisib combination therapy</td>\n",
       "      <td>melanoma</td>\n",
       "      <td>Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>vemurafenib</td>\n",
       "      <td>melanoma</td>\n",
       "      <td>Inhibition of Mutated, Activated BRAF in Metastatic Melanoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>Dabrafenib / Trametinib combination therapy</td>\n",
       "      <td>melanoma</td>\n",
       "      <td>Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>Dabrafenib / Trametinib combination therapy</td>\n",
       "      <td>melanoma</td>\n",
       "      <td>Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>trametinib / vemurafenib / dabrafenib combination therapy</td>\n",
       "      <td>gastrointestinal neuroendocrine tumor</td>\n",
       "      <td>BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>Panitumumab / Trametinib combination therapy</td>\n",
       "      <td>colorectal adenocarcinoma</td>\n",
       "      <td>Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>vemurafenib</td>\n",
       "      <td>laryngeal squamous cell carcinoma</td>\n",
       "      <td>Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>vemurafenib</td>\n",
       "      <td>skin melanoma</td>\n",
       "      <td>Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>vemurafenib</td>\n",
       "      <td>skin melanoma</td>\n",
       "      <td>Improved survival with vemurafenib in melanoma with BRAF V600E mutation</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>Dabrafenib / Trametinib combination therapy</td>\n",
       "      <td>skin melanoma</td>\n",
       "      <td>Improved overall survival in melanoma with combined dabrafenib and trametinib.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>Capecitabine / Vemurafenib / Bevacizumab combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>vemurafenib</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>Vemurafenib / Gefitinib / Cetuximab combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>dactolisib / GDC-0879 combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>PLX4720 / Nutlin-3 combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>PLX4720 / GDC0941combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>Vemurafenib / Panitumumab combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>vemurafenib</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>Vemurafenib / Panitumumab combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>ado-trastuzumab emtansine</td>\n",
       "      <td>Her2-receptor positive breast cancer</td>\n",
       "      <td>Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Trastuzumab</td>\n",
       "      <td>scrotum Paget's disease</td>\n",
       "      <td>Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Trastuzumab</td>\n",
       "      <td>gastric adenocarcinoma</td>\n",
       "      <td>Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>lapatinib</td>\n",
       "      <td>gastric adenocarcinoma</td>\n",
       "      <td>Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Pertuzumab / Trastuzumab combination therapy</td>\n",
       "      <td>bladder carcinoma</td>\n",
       "      <td>Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>afatinib</td>\n",
       "      <td>pancreatic adenocarcinoma</td>\n",
       "      <td>Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Pertuzumab / Trastuzumab combination therapy</td>\n",
       "      <td>biliary tract cancer</td>\n",
       "      <td>Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Trastuzumab / Lapatinib combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Pertuzumab / Trastuzumab combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Trastuzumab / irinotecan combination therapy</td>\n",
       "      <td>lung small cell carcinoma</td>\n",
       "      <td>Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>93</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Trastuzumab</td>\n",
       "      <td>uterine corpus serous adenocarcinoma</td>\n",
       "      <td>Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Pertuzumab / Trastuzumab combination therapy</td>\n",
       "      <td>pancreatic cancer</td>\n",
       "      <td>Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Trastuzumab</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Trastuzumab</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>ado-trastuzumab emtansine</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>dacomitinib</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Trastuzumab</td>\n",
       "      <td>endometrial cancer</td>\n",
       "      <td>Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>100</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS A146T</td>\n",
       "      <td>selumetinib / dactolisib combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>101</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS A146V</td>\n",
       "      <td>selumetinib / dactolisib combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>102</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS A146V</td>\n",
       "      <td>abemaciclib</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>103</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12C</td>\n",
       "      <td>selumetinib / dactolisib combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>104</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12C</td>\n",
       "      <td>selumetinib / docetaxel trihydrate combination therapy</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>105</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12D</td>\n",
       "      <td>MK-2206</td>\n",
       "      <td>pancreatic carcinoma</td>\n",
       "      <td>First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>106</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12D</td>\n",
       "      <td>selumetinib / dactolisib combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>107</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12D</td>\n",
       "      <td>selumetinib / dactolisib combination therapy</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>108</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12V</td>\n",
       "      <td>selumetinib / dactolisib combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>109</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12V</td>\n",
       "      <td>palbociclib</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>110</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12V</td>\n",
       "      <td>selumetinib / docetaxel trihydrate combination therapy</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>111</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G13D</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>112</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G13D</td>\n",
       "      <td>selumetinib / dactolisib combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>113 rows Ã— 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    geneSymbol.value   variantLabel.value  \\\n",
       "0    BRAF             BRAF G466V            \n",
       "1    BRAF             BRAF K601E            \n",
       "2    BRAF             BRAF K601E            \n",
       "3    BRAF             BRAF V600E            \n",
       "4    BRAF             BRAF V600E            \n",
       "5    BRAF             BRAF V600E            \n",
       "6    BRAF             BRAF V600E            \n",
       "7    BRAF             BRAF V600E            \n",
       "8    BRAF             BRAF V600E            \n",
       "9    BRAF             BRAF V600E            \n",
       "10   BRAF             BRAF V600E            \n",
       "11   BRAF             BRAF V600E            \n",
       "12   BRAF             BRAF V600E            \n",
       "13   BRAF             BRAF V600E            \n",
       "14   BRAF             BRAF V600E            \n",
       "15   BRAF             BRAF V600E            \n",
       "16   BRAF             BRAF V600E            \n",
       "17   BRAF             BRAF V600E            \n",
       "18   BRAF             BRAF V600E            \n",
       "19   BRAF             BRAF V600E            \n",
       "20   BRAF             BRAF V600E            \n",
       "21   BRAF             BRAF V600E            \n",
       "22   BRAF             BRAF V600E            \n",
       "23   BRAF             BRAF V600E            \n",
       "24   BRAF             BRAF V600E            \n",
       "25   BRAF             BRAF V600E            \n",
       "26   BRAF             BRAF V600E            \n",
       "27   BRAF             BRAF V600E            \n",
       "28   BRAF             BRAF V600E            \n",
       "29   BRAF             BRAF V600E            \n",
       "..    ...                    ...            \n",
       "83   ERBB2            ERBB2 AMPLIFICATION   \n",
       "84   ERBB2            ERBB2 AMPLIFICATION   \n",
       "85   ERBB2            ERBB2 AMPLIFICATION   \n",
       "86   ERBB2            ERBB2 AMPLIFICATION   \n",
       "87   ERBB2            ERBB2 AMPLIFICATION   \n",
       "88   ERBB2            ERBB2 AMPLIFICATION   \n",
       "89   ERBB2            ERBB2 AMPLIFICATION   \n",
       "90   ERBB2            ERBB2 AMPLIFICATION   \n",
       "91   ERBB2            ERBB2 AMPLIFICATION   \n",
       "92   ERBB2            ERBB2 AMPLIFICATION   \n",
       "93   ERBB2            ERBB2 AMPLIFICATION   \n",
       "94   ERBB2            ERBB2 AMPLIFICATION   \n",
       "95   ERBB2            ERBB2 AMPLIFICATION   \n",
       "96   ERBB2            ERBB2 AMPLIFICATION   \n",
       "97   ERBB2            ERBB2 AMPLIFICATION   \n",
       "98   ERBB2            ERBB2 AMPLIFICATION   \n",
       "99   ERBB2            ERBB2 AMPLIFICATION   \n",
       "100  KRAS             KRAS A146T            \n",
       "101  KRAS             KRAS A146V            \n",
       "102  KRAS             KRAS A146V            \n",
       "103  KRAS             KRAS G12C             \n",
       "104  KRAS             KRAS G12C             \n",
       "105  KRAS             KRAS G12D             \n",
       "106  KRAS             KRAS G12D             \n",
       "107  KRAS             KRAS G12D             \n",
       "108  KRAS             KRAS G12V             \n",
       "109  KRAS             KRAS G12V             \n",
       "110  KRAS             KRAS G12V             \n",
       "111  KRAS             KRAS G13D             \n",
       "112  KRAS             KRAS G13D             \n",
       "\n",
       "                                             treatmentLabel.value  \\\n",
       "0    vemurafenib                                                    \n",
       "1    vemurafenib                                                    \n",
       "2    trametinib                                                     \n",
       "3    cobimetinib fumarate                                           \n",
       "4    vemurafenib                                                    \n",
       "5    Dabrafenib / Trametinib combination therapy                    \n",
       "6    vemurafenib                                                    \n",
       "7    Dabrafenib / Trametinib combination therapy                    \n",
       "8    vemurafenib / cobimetinib fumarate combination therapy         \n",
       "9    pictilisib                                                     \n",
       "10   selumetinib / dactolisib combination therapy                   \n",
       "11   vemurafenib                                                    \n",
       "12   Dabrafenib / Trametinib combination therapy                    \n",
       "13   Dabrafenib / Trametinib combination therapy                    \n",
       "14   trametinib / vemurafenib / dabrafenib combination therapy      \n",
       "15   Panitumumab / Trametinib combination therapy                   \n",
       "16   vemurafenib                                                    \n",
       "17   vemurafenib                                                    \n",
       "18   vemurafenib                                                    \n",
       "19   Dabrafenib / Trametinib combination therapy                    \n",
       "20   Capecitabine / Vemurafenib / Bevacizumab combination therapy   \n",
       "21   vemurafenib                                                    \n",
       "22   Vemurafenib / Gefitinib / Cetuximab combination therapy        \n",
       "23   dabrafenib                                                     \n",
       "24   dactolisib / GDC-0879 combination therapy                      \n",
       "25   PLX4720 / Nutlin-3 combination therapy                         \n",
       "26   PLX4720 / GDC0941combination therapy                           \n",
       "27   Vemurafenib / Panitumumab combination therapy                  \n",
       "28   vemurafenib                                                    \n",
       "29   Vemurafenib / Panitumumab combination therapy                  \n",
       "..                                             ...                  \n",
       "83   ado-trastuzumab emtansine                                      \n",
       "84   Trastuzumab                                                    \n",
       "85   Trastuzumab                                                    \n",
       "86   lapatinib                                                      \n",
       "87   Pertuzumab / Trastuzumab combination therapy                   \n",
       "88   afatinib                                                       \n",
       "89   Pertuzumab / Trastuzumab combination therapy                   \n",
       "90   Trastuzumab / Lapatinib combination therapy                    \n",
       "91   Pertuzumab / Trastuzumab combination therapy                   \n",
       "92   Trastuzumab / irinotecan combination therapy                   \n",
       "93   Trastuzumab                                                    \n",
       "94   Pertuzumab / Trastuzumab combination therapy                   \n",
       "95   Trastuzumab                                                    \n",
       "96   Trastuzumab                                                    \n",
       "97   ado-trastuzumab emtansine                                      \n",
       "98   dacomitinib                                                    \n",
       "99   Trastuzumab                                                    \n",
       "100  selumetinib / dactolisib combination therapy                   \n",
       "101  selumetinib / dactolisib combination therapy                   \n",
       "102  abemaciclib                                                    \n",
       "103  selumetinib / dactolisib combination therapy                   \n",
       "104  selumetinib / docetaxel trihydrate combination therapy         \n",
       "105  MK-2206                                                        \n",
       "106  selumetinib / dactolisib combination therapy                   \n",
       "107  selumetinib / dactolisib combination therapy                   \n",
       "108  selumetinib / dactolisib combination therapy                   \n",
       "109  palbociclib                                                    \n",
       "110  selumetinib / docetaxel trihydrate combination therapy         \n",
       "111  Cetuximab                                                      \n",
       "112  selumetinib / dactolisib combination therapy                   \n",
       "\n",
       "                        diseaseLabel.value  \\\n",
       "0    cancer                                  \n",
       "1    skin melanoma                           \n",
       "2    skin melanoma                           \n",
       "3    cancer                                  \n",
       "4    ovarian cancer                          \n",
       "5    melanoma                                \n",
       "6    melanoma                                \n",
       "7    melanoma                                \n",
       "8    melanoma                                \n",
       "9    melanoma                                \n",
       "10   melanoma                                \n",
       "11   melanoma                                \n",
       "12   melanoma                                \n",
       "13   melanoma                                \n",
       "14   gastrointestinal neuroendocrine tumor   \n",
       "15   colorectal adenocarcinoma               \n",
       "16   laryngeal squamous cell carcinoma       \n",
       "17   skin melanoma                           \n",
       "18   skin melanoma                           \n",
       "19   skin melanoma                           \n",
       "20   colorectal cancer                       \n",
       "21   colorectal cancer                       \n",
       "22   colorectal cancer                       \n",
       "23   colorectal cancer                       \n",
       "24   colorectal cancer                       \n",
       "25   colorectal cancer                       \n",
       "26   colorectal cancer                       \n",
       "27   colorectal cancer                       \n",
       "28   colorectal cancer                       \n",
       "29   colorectal cancer                       \n",
       "..                 ...                       \n",
       "83   Her2-receptor positive breast cancer    \n",
       "84   scrotum Paget's disease                 \n",
       "85   gastric adenocarcinoma                  \n",
       "86   gastric adenocarcinoma                  \n",
       "87   bladder carcinoma                       \n",
       "88   pancreatic adenocarcinoma               \n",
       "89   biliary tract cancer                    \n",
       "90   colorectal cancer                       \n",
       "91   colorectal cancer                       \n",
       "92   lung small cell carcinoma               \n",
       "93   uterine corpus serous adenocarcinoma    \n",
       "94   pancreatic cancer                       \n",
       "95   non-small-cell lung carcinoma           \n",
       "96   non-small-cell lung carcinoma           \n",
       "97   non-small-cell lung carcinoma           \n",
       "98   non-small-cell lung carcinoma           \n",
       "99   endometrial cancer                      \n",
       "100  colorectal cancer                       \n",
       "101  colorectal cancer                       \n",
       "102  non-small-cell lung carcinoma           \n",
       "103  colorectal cancer                       \n",
       "104  non-small-cell lung carcinoma           \n",
       "105  pancreatic carcinoma                    \n",
       "106  colorectal cancer                       \n",
       "107  non-small-cell lung carcinoma           \n",
       "108  colorectal cancer                       \n",
       "109  non-small-cell lung carcinoma           \n",
       "110  non-small-cell lung carcinoma           \n",
       "111  colorectal cancer                       \n",
       "112  colorectal cancer                       \n",
       "\n",
       "                                                                                                                                                                                                             referenceLabel.value  \n",
       "0    Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.                                                                        \n",
       "1    BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors                                                                                                                                            \n",
       "2    BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors                                                                                                                                            \n",
       "3    Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers                                                                                                                                    \n",
       "4    Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.                                                                        \n",
       "5    Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations                                                                                                                                                         \n",
       "6    Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study                                                          \n",
       "7    Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.                                                                                                                                      \n",
       "8    Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.                                                                                                                                                                \n",
       "9    First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.                                                           \n",
       "10   Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade                                                                         \n",
       "11   Inhibition of Mutated, Activated BRAF in Metastatic Melanoma                                                                                                                                                                  \n",
       "12   Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.                                                                                                                                                    \n",
       "13   Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.                                                                                                                                                       \n",
       "14   BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.                                                                                                \n",
       "15   Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.                                                                                                                                  \n",
       "16   Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.                                                                        \n",
       "17   Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib                                                                                                                                                       \n",
       "18   Improved survival with vemurafenib in melanoma with BRAF V600E mutation                                                                                                                                                       \n",
       "19   Improved overall survival in melanoma with combined dabrafenib and trametinib.                                                                                                                                                \n",
       "20   Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.                                                                                                                      \n",
       "21   Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.                                                                                                                      \n",
       "22   Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.                                                                                                                               \n",
       "23   Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.                                                                                                   \n",
       "24   Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.                                                                                                                 \n",
       "25   Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.                                                                                                                  \n",
       "26   A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.                                                                                                     \n",
       "27   Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.                                                                                                                        \n",
       "28   Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.                                                                                                                               \n",
       "29   MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.                                                                              \n",
       "..                                                                                                                                                ...                                                                              \n",
       "83   Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.                                  \n",
       "84   Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.                            \n",
       "85   Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.      \n",
       "86   Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.                                          \n",
       "87   Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.                                                                        \n",
       "88   Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.                                                       \n",
       "89   Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.                                                                        \n",
       "90   Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.  \n",
       "91   Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.                                                                        \n",
       "92   Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.                                                                                     \n",
       "93   Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.                                                                                                                   \n",
       "94   Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.                                                                        \n",
       "95   Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.                                                                                                   \n",
       "96   Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.                                                                                      \n",
       "97   Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.                                                                                                                  \n",
       "98   Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors                                        \n",
       "99   Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.                                                                                   \n",
       "100  Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.                                                                \n",
       "101  Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.                                                                \n",
       "102  Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.                                                                                     \n",
       "103  Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.                                                                \n",
       "104  Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer                                                                               \n",
       "105  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.                                                                                                                     \n",
       "106  Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.                                                                \n",
       "107  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.                                                                                                                     \n",
       "108  Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.                                                                \n",
       "109  A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.                                                                                             \n",
       "110  Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer                                                                               \n",
       "111  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.                                                                                \n",
       "112  Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.                                                                \n",
       "\n",
       "[113 rows x 5 columns]"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX wdt: <http://www.wikidata.org/prop/direct/>\n",
    "PREFIX owl: <http://www.w3.org/2002/07/owl#>\n",
    "PREFIX pq: <http://www.wikidata.org/prop/qualifier/>\n",
    "PREFIX ps: <http://www.wikidata.org/prop/statement/>\n",
    "PREFIX pr: <http://www.wikidata.org/prop/reference/>\n",
    "PREFIX p: <http://www.wikidata.org/prop/>\n",
    "PREFIX prov: <http://www.w3.org/ns/prov#>\n",
    "PREFIX wikibase: <http://wikiba.se/ontology#>\n",
    "PREFIX bd: <http://www.bigdata.com/rdf#>\n",
    "PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n",
    "select distinct ?geneSymbol ?variantLabel ?treatmentLabel ?diseaseLabel ?referenceLabel\n",
    "\n",
    "where {\n",
    "\n",
    "    SERVICE <https://query.wikidata.org/sparql> {\n",
    "        ?variant wdt:P3329 ?id .\n",
    "        ?variant p:P3354 [ ps:P3354 ?treatment ; \n",
    "                           pq:P2175 ?disease ;\n",
    "                           prov:wasDerivedFrom ?source ].\n",
    "        ?source pr:P248 ?reference    \n",
    "\n",
    "        SERVICE wikibase:label { \n",
    "            bd:serviceParam wikibase:language \"en\" . \n",
    "            ?variant rdfs:label ?variantLabel .\n",
    "            ?treatment rdfs:label ?treatmentLabel .\n",
    "            ?disease rdfs:label ?diseaseLabel .\n",
    "            ?reference rdfs:label ?referenceLabel\n",
    "        }\n",
    "    }\n",
    "\n",
    "\n",
    "    ?case a :Case ;\n",
    "          :hasDescendant ?mouse ;\n",
    "          :hasDescendant ?node .\n",
    "    ?mouse a :Biomouse ;\n",
    "           :has_annotation ?ann .\n",
    "    ?ann :has_reference ?ref .\n",
    "    ?ref a :drug_response .\n",
    "    ?node :has_annotation ?ann2 .\n",
    "    ?ann2 :has_reference ?variant .\n",
    "    ?gene :has_variant ?variant.\n",
    "    OPTIONAL {?variant :alt_p ?alt_p }\n",
    "    ?gene :symbol ?geneSymbol\n",
    "    VALUES ?geneSymbol {'KRAS' 'EGFR' 'BRAF' 'ERBB2'}\n",
    "    ?variant a ?annotation_Type.\n",
    "    VALUES ?annotation_Type { :sequence_alteration :feature_amplification }\n",
    "}\n",
    "order by ?geneSymbol\n",
    "\"\"\"\n",
    "\n",
    "# get data\n",
    "result_table = utils.query(SEMALYTICS_ENDPOINT, my_query)\n",
    "\n",
    "# there you go\n",
    "result_table[['geneSymbol.value', 'variantLabel.value', 'treatmentLabel.value', 'diseaseLabel.value', 'referenceLabel.value']]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='neg'></a>\n",
    "## Negative therapeutic predictors\n",
    "\n",
    "We can use the **variants occurrences** annotated in the local database for querying associated **negative response predictions** to drugs. Moreover, we retrieve also the scientific article from where the evidence comes and the relative medical condition treated."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>geneSymbol.value</th>\n",
       "      <th>variantLabel.value</th>\n",
       "      <th>treatmentLabel.value</th>\n",
       "      <th>diseaseLabel.value</th>\n",
       "      <th>referenceLabel.value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>vemurafenib</td>\n",
       "      <td>melanoma</td>\n",
       "      <td>Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>pd-0325901</td>\n",
       "      <td>melanoma</td>\n",
       "      <td>Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>trametinib</td>\n",
       "      <td>melanoma</td>\n",
       "      <td>Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>Panitumumab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>irinotecan</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>Oxaliplatin</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>BRAF V600E</td>\n",
       "      <td>dabrafenib</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR G465R</td>\n",
       "      <td>Panitumumab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR G465R</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR AMPLIFICATION</td>\n",
       "      <td>osimertinib</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR AMPLIFICATION</td>\n",
       "      <td>rociletinib</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Panitumumab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Cetuximab / capecitabine / Oxaliplatin combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>gefitinib</td>\n",
       "      <td>adenocarcinoma of the lung</td>\n",
       "      <td>Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>ERBB2</td>\n",
       "      <td>ERBB2 AMPLIFICATION</td>\n",
       "      <td>erlotinib</td>\n",
       "      <td>adenocarcinoma of the lung</td>\n",
       "      <td>Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS A146T</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Genomic and biological characterization of exon 4 KRAS mutations in human cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12A</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12A</td>\n",
       "      <td>melphalan</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12A</td>\n",
       "      <td>melphalan</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12A</td>\n",
       "      <td>melphalan</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12A</td>\n",
       "      <td>melphalan</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12A</td>\n",
       "      <td>gefitinib</td>\n",
       "      <td>lung cancer</td>\n",
       "      <td>PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12A</td>\n",
       "      <td>gefitinib</td>\n",
       "      <td>adenocarcinoma of the lung</td>\n",
       "      <td>Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12A</td>\n",
       "      <td>erlotinib</td>\n",
       "      <td>adenocarcinoma of the lung</td>\n",
       "      <td>Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12C</td>\n",
       "      <td>gefitinib</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12C</td>\n",
       "      <td>erlotinib</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12C</td>\n",
       "      <td>melphalan</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12C</td>\n",
       "      <td>melphalan</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12C</td>\n",
       "      <td>gefitinib</td>\n",
       "      <td>lung cancer</td>\n",
       "      <td>PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12D</td>\n",
       "      <td>vemurafenib</td>\n",
       "      <td>melanoma</td>\n",
       "      <td>Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12D</td>\n",
       "      <td>Panitumumab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12D</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12D</td>\n",
       "      <td>vemurafenib</td>\n",
       "      <td>hairy cell leukemia</td>\n",
       "      <td>Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12D</td>\n",
       "      <td>melphalan</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12D</td>\n",
       "      <td>melphalan</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12D</td>\n",
       "      <td>gefitinib</td>\n",
       "      <td>lung cancer</td>\n",
       "      <td>PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12R</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12S</td>\n",
       "      <td>Panitumumab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12S</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12S</td>\n",
       "      <td>melphalan</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12S</td>\n",
       "      <td>melphalan</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12S</td>\n",
       "      <td>melphalan</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12S</td>\n",
       "      <td>gefitinib</td>\n",
       "      <td>lung cancer</td>\n",
       "      <td>PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12V</td>\n",
       "      <td>crizotinib</td>\n",
       "      <td>cancer</td>\n",
       "      <td>Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12V</td>\n",
       "      <td>Panitumumab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12V</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12V</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G12V</td>\n",
       "      <td>gefitinib</td>\n",
       "      <td>lung cancer</td>\n",
       "      <td>PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G13D</td>\n",
       "      <td>Panitumumab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G13D</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G13D</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G13D</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G13D</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   geneSymbol.value   variantLabel.value  \\\n",
       "0   BRAF             BRAF V600E            \n",
       "1   BRAF             BRAF V600E            \n",
       "2   BRAF             BRAF V600E            \n",
       "3   BRAF             BRAF V600E            \n",
       "4   BRAF             BRAF V600E            \n",
       "5   BRAF             BRAF V600E            \n",
       "6   BRAF             BRAF V600E            \n",
       "7   BRAF             BRAF V600E            \n",
       "8   EGFR             EGFR G465R            \n",
       "9   EGFR             EGFR G465R            \n",
       "10  EGFR             EGFR AMPLIFICATION    \n",
       "11  EGFR             EGFR AMPLIFICATION    \n",
       "12  ERBB2            ERBB2 AMPLIFICATION   \n",
       "13  ERBB2            ERBB2 AMPLIFICATION   \n",
       "14  ERBB2            ERBB2 AMPLIFICATION   \n",
       "15  ERBB2            ERBB2 AMPLIFICATION   \n",
       "16  ERBB2            ERBB2 AMPLIFICATION   \n",
       "17  ERBB2            ERBB2 AMPLIFICATION   \n",
       "18  ERBB2            ERBB2 AMPLIFICATION   \n",
       "19  KRAS             KRAS A146T            \n",
       "20  KRAS             KRAS G12A             \n",
       "21  KRAS             KRAS G12A             \n",
       "22  KRAS             KRAS G12A             \n",
       "23  KRAS             KRAS G12A             \n",
       "24  KRAS             KRAS G12A             \n",
       "25  KRAS             KRAS G12A             \n",
       "26  KRAS             KRAS G12A             \n",
       "27  KRAS             KRAS G12A             \n",
       "28  KRAS             KRAS G12C             \n",
       "29  KRAS             KRAS G12C             \n",
       "30  KRAS             KRAS G12C             \n",
       "31  KRAS             KRAS G12C             \n",
       "32  KRAS             KRAS G12C             \n",
       "33  KRAS             KRAS G12D             \n",
       "34  KRAS             KRAS G12D             \n",
       "35  KRAS             KRAS G12D             \n",
       "36  KRAS             KRAS G12D             \n",
       "37  KRAS             KRAS G12D             \n",
       "38  KRAS             KRAS G12D             \n",
       "39  KRAS             KRAS G12D             \n",
       "40  KRAS             KRAS G12R             \n",
       "41  KRAS             KRAS G12S             \n",
       "42  KRAS             KRAS G12S             \n",
       "43  KRAS             KRAS G12S             \n",
       "44  KRAS             KRAS G12S             \n",
       "45  KRAS             KRAS G12S             \n",
       "46  KRAS             KRAS G12S             \n",
       "47  KRAS             KRAS G12V             \n",
       "48  KRAS             KRAS G12V             \n",
       "49  KRAS             KRAS G12V             \n",
       "50  KRAS             KRAS G12V             \n",
       "51  KRAS             KRAS G12V             \n",
       "52  KRAS             KRAS G13D             \n",
       "53  KRAS             KRAS G13D             \n",
       "54  KRAS             KRAS G13D             \n",
       "55  KRAS             KRAS G13D             \n",
       "56  KRAS             KRAS G13D             \n",
       "\n",
       "                                          treatmentLabel.value  \\\n",
       "0   vemurafenib                                                  \n",
       "1   pd-0325901                                                   \n",
       "2   trametinib                                                   \n",
       "3   Panitumumab                                                  \n",
       "4   Cetuximab                                                    \n",
       "5   irinotecan                                                   \n",
       "6   Oxaliplatin                                                  \n",
       "7   dabrafenib                                                   \n",
       "8   Panitumumab                                                  \n",
       "9   Cetuximab                                                    \n",
       "10  osimertinib                                                  \n",
       "11  rociletinib                                                  \n",
       "12  Cetuximab                                                    \n",
       "13  Panitumumab                                                  \n",
       "14  Cetuximab                                                    \n",
       "15  Cetuximab / capecitabine / Oxaliplatin combination therapy   \n",
       "16  Cetuximab                                                    \n",
       "17  gefitinib                                                    \n",
       "18  erlotinib                                                    \n",
       "19  Cetuximab                                                    \n",
       "20  regorafenib                                                  \n",
       "21  melphalan                                                    \n",
       "22  melphalan                                                    \n",
       "23  melphalan                                                    \n",
       "24  melphalan                                                    \n",
       "25  gefitinib                                                    \n",
       "26  gefitinib                                                    \n",
       "27  erlotinib                                                    \n",
       "28  gefitinib                                                    \n",
       "29  erlotinib                                                    \n",
       "30  melphalan                                                    \n",
       "31  melphalan                                                    \n",
       "32  gefitinib                                                    \n",
       "33  vemurafenib                                                  \n",
       "34  Panitumumab                                                  \n",
       "35  Cetuximab                                                    \n",
       "36  vemurafenib                                                  \n",
       "37  melphalan                                                    \n",
       "38  melphalan                                                    \n",
       "39  gefitinib                                                    \n",
       "40  Cetuximab                                                    \n",
       "41  Panitumumab                                                  \n",
       "42  Cetuximab                                                    \n",
       "43  melphalan                                                    \n",
       "44  melphalan                                                    \n",
       "45  melphalan                                                    \n",
       "46  gefitinib                                                    \n",
       "47  crizotinib                                                   \n",
       "48  Panitumumab                                                  \n",
       "49  Cetuximab                                                    \n",
       "50  Cetuximab                                                    \n",
       "51  gefitinib                                                    \n",
       "52  Panitumumab                                                  \n",
       "53  Cetuximab                                                    \n",
       "54  Cetuximab                                                    \n",
       "55  Cetuximab                                                    \n",
       "56  Cetuximab                                                    \n",
       "\n",
       "               diseaseLabel.value  \\\n",
       "0   melanoma                        \n",
       "1   melanoma                        \n",
       "2   melanoma                        \n",
       "3   colorectal cancer               \n",
       "4   colorectal cancer               \n",
       "5   colorectal cancer               \n",
       "6   colorectal cancer               \n",
       "7   non-small-cell lung carcinoma   \n",
       "8   colorectal cancer               \n",
       "9   colorectal cancer               \n",
       "10  non-small-cell lung carcinoma   \n",
       "11  non-small-cell lung carcinoma   \n",
       "12  colorectal cancer               \n",
       "13  colorectal cancer               \n",
       "14  colorectal cancer               \n",
       "15  colorectal cancer               \n",
       "16  colorectal cancer               \n",
       "17  adenocarcinoma of the lung      \n",
       "18  adenocarcinoma of the lung      \n",
       "19  colorectal cancer               \n",
       "20  colorectal cancer               \n",
       "21  multiple myeloma                \n",
       "22  multiple myeloma                \n",
       "23  multiple myeloma                \n",
       "24  multiple myeloma                \n",
       "25  lung cancer                     \n",
       "26  adenocarcinoma of the lung      \n",
       "27  adenocarcinoma of the lung      \n",
       "28  colorectal cancer               \n",
       "29  colorectal cancer               \n",
       "30  multiple myeloma                \n",
       "31  multiple myeloma                \n",
       "32  lung cancer                     \n",
       "33  melanoma                        \n",
       "34  colorectal cancer               \n",
       "35  colorectal cancer               \n",
       "36  hairy cell leukemia             \n",
       "37  multiple myeloma                \n",
       "38  multiple myeloma                \n",
       "39  lung cancer                     \n",
       "40  colorectal cancer               \n",
       "41  colorectal cancer               \n",
       "42  colorectal cancer               \n",
       "43  multiple myeloma                \n",
       "44  multiple myeloma                \n",
       "45  multiple myeloma                \n",
       "46  lung cancer                     \n",
       "47  cancer                          \n",
       "48  colorectal cancer               \n",
       "49  colorectal cancer               \n",
       "50  colorectal cancer               \n",
       "51  lung cancer                     \n",
       "52  colorectal cancer               \n",
       "53  colorectal cancer               \n",
       "54  colorectal cancer               \n",
       "55  colorectal cancer               \n",
       "56  colorectal cancer               \n",
       "\n",
       "                                                                                                                                                                                    referenceLabel.value  \n",
       "0   Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.                                                                                                               \n",
       "1   Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.                                                                                                               \n",
       "2   Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.                                                                                                               \n",
       "3   Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer                                         \n",
       "4   Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer                                         \n",
       "5   Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.                                                                \n",
       "6   Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.                                                                \n",
       "7   Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.                                                          \n",
       "8   The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.                                             \n",
       "9   The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.                                             \n",
       "10  Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.                                        \n",
       "11  Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.                                        \n",
       "12  A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.                          \n",
       "13  HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.                                                             \n",
       "14  HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.                                                             \n",
       "15  HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.  \n",
       "16  HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.                                                                             \n",
       "17  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.                                                                     \n",
       "18  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.                                                                     \n",
       "19  Genomic and biological characterization of exon 4 KRAS mutations in human cancer                                                                                                                      \n",
       "20  KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.                                                                                          \n",
       "21  Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation.               \n",
       "22  Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.                                             \n",
       "23  Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response.                                                         \n",
       "24  Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.                                                          \n",
       "25  PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.                                                                      \n",
       "26  Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones                                              \n",
       "27  Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones                                              \n",
       "28  The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.         \n",
       "29  The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.         \n",
       "30  Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.                                             \n",
       "31  Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.                                                          \n",
       "32  PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.                                                                      \n",
       "33  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy                                                                                                                    \n",
       "34  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.                                                                                 \n",
       "35  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.                                                                                 \n",
       "36  Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia                                                                                                                                   \n",
       "37  Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.                                             \n",
       "38  Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.                                                          \n",
       "39  PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.                                                                      \n",
       "40  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer                                                                                                         \n",
       "41  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.                                                                                 \n",
       "42  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.                                                                                 \n",
       "43  Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.                                             \n",
       "44  Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response.                                                         \n",
       "45  Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.                                                          \n",
       "46  PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.                                                                      \n",
       "47  Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary.                                                                                                         \n",
       "48  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.                                                                                 \n",
       "49  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.                                                                                 \n",
       "50  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.                                                        \n",
       "51  PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.                                                                      \n",
       "52  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.                                                                                 \n",
       "53  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.                                                                                 \n",
       "54  Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.                                                                                                            \n",
       "55  Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.                                                                                   \n",
       "56  Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.                                           "
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX wdt: <http://www.wikidata.org/prop/direct/>\n",
    "PREFIX owl: <http://www.w3.org/2002/07/owl#>\n",
    "PREFIX pq: <http://www.wikidata.org/prop/qualifier/>\n",
    "PREFIX ps: <http://www.wikidata.org/prop/statement/>\n",
    "PREFIX pr: <http://www.wikidata.org/prop/reference/>\n",
    "PREFIX p: <http://www.wikidata.org/prop/>\n",
    "PREFIX prov: <http://www.w3.org/ns/prov#>\n",
    "PREFIX wikibase: <http://wikiba.se/ontology#>\n",
    "PREFIX bd: <http://www.bigdata.com/rdf#>\n",
    "PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n",
    "select distinct ?geneSymbol ?variantLabel ?treatmentLabel ?diseaseLabel ?referenceLabel\n",
    "\n",
    "where {\n",
    "\n",
    "    SERVICE <https://query.wikidata.org/sparql> {\n",
    "        ?variant wdt:P3329 ?id .\n",
    "        ?variant p:P3355 [ ps:P3355 ?treatment ; \n",
    "                           pq:P2175 ?disease ;\n",
    "                           prov:wasDerivedFrom ?source ].\n",
    "        ?source pr:P248 ?reference    \n",
    "\n",
    "        SERVICE wikibase:label { \n",
    "            bd:serviceParam wikibase:language \"en\" . \n",
    "            ?variant rdfs:label ?variantLabel .\n",
    "            ?treatment rdfs:label ?treatmentLabel .\n",
    "            ?disease rdfs:label ?diseaseLabel .\n",
    "            ?reference rdfs:label ?referenceLabel\n",
    "        }\n",
    "    }\n",
    "\n",
    "\n",
    "    ?case a :Case ;\n",
    "          :hasDescendant ?mouse ;\n",
    "          :hasDescendant ?node .\n",
    "    ?mouse a :Biomouse ;\n",
    "           :has_annotation ?ann .\n",
    "    ?ann :has_reference ?ref .\n",
    "    ?ref a :drug_response .\n",
    "    ?node :has_annotation ?ann2 .\n",
    "    ?ann2 :has_reference ?variant .\n",
    "    ?gene :has_variant ?variant.\n",
    "    OPTIONAL {?variant :alt_p ?alt_p }\n",
    "    ?gene :symbol ?geneSymbol\n",
    "    VALUES ?geneSymbol {'KRAS' 'EGFR' 'BRAF' 'ERBB2'}\n",
    "    ?variant a ?annotation_Type.\n",
    "    VALUES ?annotation_Type { :sequence_alteration :feature_amplification }\n",
    "}\n",
    "order by ?geneSymbol\n",
    "\"\"\"\n",
    "\n",
    "# get data\n",
    "result_table = utils.query(SEMALYTICS_ENDPOINT, my_query)\n",
    "\n",
    "# there you go\n",
    "result_table[['geneSymbol.value', 'variantLabel.value', 'treatmentLabel.value', 'diseaseLabel.value', 'referenceLabel.value']]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='case'></a>\n",
    "### Drugs predictions for a specific case\n",
    "\n",
    "We can use the connection to Wikidata for querying evidences of drug responses predictions (i.e., positive or negative) associated with variants harbored by a specific case (i.e., _id=CRC0481_)\n",
    "\n",
    "**Positive responses predictions**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>geneSymbol.value</th>\n",
       "      <th>variantLabel.value</th>\n",
       "      <th>treatmentLabel.value</th>\n",
       "      <th>diseaseLabel.value</th>\n",
       "      <th>referenceLabel.value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR AMPLIFICATION</td>\n",
       "      <td>Cetuximab / platinum / fluorouracil combination therapy</td>\n",
       "      <td>head and neck squamous cell carcinoma</td>\n",
       "      <td>Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR AMPLIFICATION</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR AMPLIFICATION</td>\n",
       "      <td>Panitumumab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR AMPLIFICATION</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR AMPLIFICATION</td>\n",
       "      <td>gefitinib</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR AMPLIFICATION</td>\n",
       "      <td>erlotinib</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G13D</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G13D</td>\n",
       "      <td>selumetinib / dactolisib combination therapy</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  geneSymbol.value  variantLabel.value  \\\n",
       "0  EGFR             EGFR AMPLIFICATION   \n",
       "1  EGFR             EGFR AMPLIFICATION   \n",
       "2  EGFR             EGFR AMPLIFICATION   \n",
       "3  EGFR             EGFR AMPLIFICATION   \n",
       "4  EGFR             EGFR AMPLIFICATION   \n",
       "5  EGFR             EGFR AMPLIFICATION   \n",
       "6  KRAS             KRAS G13D            \n",
       "7  KRAS             KRAS G13D            \n",
       "\n",
       "                                      treatmentLabel.value  \\\n",
       "0  Cetuximab / platinum / fluorouracil combination therapy   \n",
       "1  Cetuximab                                                 \n",
       "2  Panitumumab                                               \n",
       "3  Cetuximab                                                 \n",
       "4  gefitinib                                                 \n",
       "5  erlotinib                                                 \n",
       "6  Cetuximab                                                 \n",
       "7  selumetinib / dactolisib combination therapy              \n",
       "\n",
       "                      diseaseLabel.value  \\\n",
       "0  head and neck squamous cell carcinoma   \n",
       "1  colorectal cancer                       \n",
       "2  colorectal cancer                       \n",
       "3  colorectal cancer                       \n",
       "4  non-small-cell lung carcinoma           \n",
       "5  non-small-cell lung carcinoma           \n",
       "6  colorectal cancer                       \n",
       "7  colorectal cancer                       \n",
       "\n",
       "                                                                                                                                                                                                                                   referenceLabel.value  \n",
       "0  Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.  \n",
       "1  Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.                                                                                  \n",
       "2  EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.                                                                                         \n",
       "3  EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.                                                                                         \n",
       "4  Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.                                                                                                                                                            \n",
       "5  Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.                                                                                                                                                            \n",
       "6  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.                                                                                                        \n",
       "7  Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.                                                                                        "
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX wdt: <http://www.wikidata.org/prop/direct/>\n",
    "PREFIX owl: <http://www.w3.org/2002/07/owl#>\n",
    "PREFIX pq: <http://www.wikidata.org/prop/qualifier/>\n",
    "PREFIX ps: <http://www.wikidata.org/prop/statement/>\n",
    "PREFIX pr: <http://www.wikidata.org/prop/reference/>\n",
    "PREFIX p: <http://www.wikidata.org/prop/>\n",
    "PREFIX prov: <http://www.w3.org/ns/prov#>\n",
    "PREFIX wikibase: <http://wikiba.se/ontology#>\n",
    "PREFIX bd: <http://www.bigdata.com/rdf#>\n",
    "PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n",
    "select distinct ?geneSymbol ?variantLabel ?treatmentLabel ?diseaseLabel ?referenceLabel\n",
    "where {\n",
    "    SERVICE <https://query.wikidata.org/sparql> {\n",
    "        ?variant wdt:P3329 ?id .\n",
    "        ?variant p:P3354 [ ps:P3354 ?treatment ; \n",
    "                           pq:P2175 ?disease ;\n",
    "                           prov:wasDerivedFrom ?source ].\n",
    "        ?source pr:P248 ?reference\n",
    "        \n",
    "        SERVICE wikibase:label { \n",
    "            bd:serviceParam wikibase:language \"en\" . \n",
    "            ?variant rdfs:label ?variantLabel .\n",
    "            ?treatment rdfs:label ?treatmentLabel .\n",
    "            ?disease rdfs:label ?diseaseLabel .\n",
    "            ?reference rdfs:label ?referenceLabel .\n",
    "        }\n",
    "    }\n",
    "\n",
    "\n",
    "    :CRC0481 :hasDescendant ?node .\n",
    "    ?node :has_annotation ?ann2 .\n",
    "    ?ann2 :has_reference ?variant .\n",
    "    ?gene :has_variant ?variant.\n",
    "    OPTIONAL {?variant :alt_p ?alt_p }\n",
    "    ?gene :symbol ?geneSymbol\n",
    "    VALUES ?geneSymbol {'KRAS' 'EGFR' 'BRAF' 'ERBB2'}\n",
    "    ?variant a ?annotation_Type.\n",
    "    VALUES ?annotation_Type { :sequence_alteration :feature_amplification }\n",
    "}\n",
    "\n",
    "order by ?geneSymbol\n",
    "\n",
    "\"\"\"\n",
    "\n",
    "# get data\n",
    "result_table = utils.query(SEMALYTICS_ENDPOINT, my_query)\n",
    "\n",
    "# there you go\n",
    "result_table[['geneSymbol.value', 'variantLabel.value', 'treatmentLabel.value', 'diseaseLabel.value', 'referenceLabel.value']]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**Negative responses predictions**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>geneSymbol.value</th>\n",
       "      <th>variantLabel.value</th>\n",
       "      <th>treatmentLabel.value</th>\n",
       "      <th>diseaseLabel.value</th>\n",
       "      <th>referenceLabel.value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR AMPLIFICATION</td>\n",
       "      <td>osimertinib</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR AMPLIFICATION</td>\n",
       "      <td>rociletinib</td>\n",
       "      <td>non-small-cell lung carcinoma</td>\n",
       "      <td>Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G13D</td>\n",
       "      <td>Panitumumab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G13D</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G13D</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G13D</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>KRAS</td>\n",
       "      <td>KRAS G13D</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  geneSymbol.value  variantLabel.value treatmentLabel.value  \\\n",
       "0  EGFR             EGFR AMPLIFICATION  osimertinib           \n",
       "1  EGFR             EGFR AMPLIFICATION  rociletinib           \n",
       "2  KRAS             KRAS G13D           Panitumumab           \n",
       "3  KRAS             KRAS G13D           Cetuximab             \n",
       "4  KRAS             KRAS G13D           Cetuximab             \n",
       "5  KRAS             KRAS G13D           Cetuximab             \n",
       "6  KRAS             KRAS G13D           Cetuximab             \n",
       "\n",
       "              diseaseLabel.value  \\\n",
       "0  non-small-cell lung carcinoma   \n",
       "1  non-small-cell lung carcinoma   \n",
       "2  colorectal cancer               \n",
       "3  colorectal cancer               \n",
       "4  colorectal cancer               \n",
       "5  colorectal cancer               \n",
       "6  colorectal cancer               \n",
       "\n",
       "                                                                                                                                             referenceLabel.value  \n",
       "0  Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.  \n",
       "1  Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.  \n",
       "2  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.                                           \n",
       "3  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.                                           \n",
       "4  Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.                                                                      \n",
       "5  Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.                                             \n",
       "6  Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.     "
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "my_query = \"\"\"\n",
    "PREFIX : <http://las.ircc.it/ontology/annotationplatform#>\n",
    "PREFIX wdt: <http://www.wikidata.org/prop/direct/>\n",
    "PREFIX owl: <http://www.w3.org/2002/07/owl#>\n",
    "PREFIX pq: <http://www.wikidata.org/prop/qualifier/>\n",
    "PREFIX ps: <http://www.wikidata.org/prop/statement/>\n",
    "PREFIX pr: <http://www.wikidata.org/prop/reference/>\n",
    "PREFIX p: <http://www.wikidata.org/prop/>\n",
    "PREFIX prov: <http://www.w3.org/ns/prov#>\n",
    "PREFIX wikibase: <http://wikiba.se/ontology#>\n",
    "PREFIX bd: <http://www.bigdata.com/rdf#>\n",
    "PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n",
    "select distinct ?geneSymbol ?variantLabel ?treatmentLabel ?diseaseLabel ?referenceLabel\n",
    "where {\n",
    "    SERVICE <https://query.wikidata.org/sparql> {\n",
    "        ?variant wdt:P3329 ?id .\n",
    "        ?variant p:P3355 [ ps:P3355 ?treatment ; \n",
    "                           pq:P2175 ?disease ;\n",
    "                           prov:wasDerivedFrom ?source ].\n",
    "        ?source pr:P248 ?reference\n",
    "        \n",
    "        SERVICE wikibase:label { \n",
    "            bd:serviceParam wikibase:language \"en\" . \n",
    "            ?variant rdfs:label ?variantLabel .\n",
    "            ?treatment rdfs:label ?treatmentLabel .\n",
    "            ?disease rdfs:label ?diseaseLabel .\n",
    "            ?reference rdfs:label ?referenceLabel .\n",
    "        }\n",
    "    }\n",
    "\n",
    "\n",
    "    :CRC0481 :hasDescendant ?node .\n",
    "    ?node :has_annotation ?ann2 .\n",
    "    ?ann2 :has_reference ?variant .\n",
    "    ?gene :has_variant ?variant.\n",
    "    OPTIONAL {?variant :alt_p ?alt_p }\n",
    "    ?gene :symbol ?geneSymbol\n",
    "    VALUES ?geneSymbol {'KRAS' 'EGFR' 'BRAF' 'ERBB2'}\n",
    "    ?variant a ?annotation_Type.\n",
    "    VALUES ?annotation_Type { :sequence_alteration :feature_amplification }\n",
    "}\n",
    "\n",
    "order by ?geneSymbol\n",
    "\n",
    "\"\"\"\n",
    "\n",
    "# get data\n",
    "result_table = utils.query(SEMALYTICS_ENDPOINT, my_query)\n",
    "\n",
    "# there you go\n",
    "result_table[['geneSymbol.value', 'variantLabel.value', 'treatmentLabel.value', 'diseaseLabel.value', 'referenceLabel.value']]"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
